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Proper maternal nutrition is critical for early embryonic development. Despite 
overwhelming epidemiologic data indicating the benefits nutrient supplementation for the 
developing organism we do not fully understand the genetics of predisposition to 
abnormal developmental phenotypes when faced with suboptimal nutrient levels. 
 Copper is an essential nutrient required for critical biochemical processes. Severe 
defects in copper homeostasis lead to significant disease typified by the X-linked 
recessive disorder Menkes disease. Patients with Menkes disease have cutis laxa, bone 
deformities, hypopigmentation, arterial malformation, and neurodegeneration due to 
copper deficiency caused by loss-of-function mutations in ATP7A, a copper transport 
protein. Despite the critical requirement for adequate copper nutrition and the 
characterization of key copper transport proteins there remain significant gaps in our 
understanding of copper metabolism.  
In order to better understand both the cell metabolic and developmental 
requirements for copper our laboratory has defined a zebrafish model of severe copper 
deficiency. The copper chelator neocuproine causes a Menkes-like phenotype in wild-
 iii 
type zebrafish embryos and the mutant calamity which phenocopies neocuproine treated 
embryos contains a null allele of atp7a.  
In this thesis we build upon this previous model in two ways in order to address 
the problem of treatment of Menkes disease and to define novel pathways important for 
copper metabolism. The first body of work uses small-molecule modifiers of mRNA 
processing (morpholinos) to correct splicing defects which cause Menkes disease 
phenotypes in zebrafish embryos. Since about 20% of human disease causing mutations 
are due to splicing defects this approach may be directly applicable to a wide array of 
human diseases. The second body of work uses a forward chemical-genetic screen for 
zebrafish mutants sensitive to mild copper deficiency. Screening mutagenized embryos 
exposed to subthreshold doses of the chelator neocuproine for copper deficiency 
phenotypes resulted in two mutants. The first, containing a hypomorphic allele of atp7a 
demonstrates the effect of maternal nutrition and genetics on embryonic development. 
The second contains a loss-of-function mutation in the vacuolar proton pump leading to a 
severe embyronic lethal phenotype which is sensitive to copper chelation. This implicates 
pH gradients in the metabolism of copper in zebrafish. 
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Purpose of review 
Reports of the neurologic findings in adults with acquired copper deficiency as well as 
the development of novel models for Menkes disease have permitted a greater 
understanding of the role of copper in the central nervous system. A role of mitochondrial 
copper homeostasis in cellular energy metabolism suggests roles for this metal in cellular 
differentiation and biochemical adaptation.  
Recent findings 
Acquired copper deficiency in adults is reported with increasing frequency, often without 
any identifiable cause. Chemical genetic studies identified a zebrafish model of Menkes 
disease that can be used for high-throughput therapeutics and revealed a hierarchy of 
copper distribution during development. Studies in mice reveal that the copper transport 
protein Ctr1 is essential for intestinal copper absorption and suggest a unique role for 
copper in axonal extension, excitotoxic cell death and synaptic plasticity in the central 
nervous system. Lastly, recent biochemical studies indicate a central role for the 
mitochondrial matrix in cellular copper metabolism. 
Summary 
The recent developments in our understanding of copper deficiency and copper 
homeostasis outlined in this review provide an exciting platform for future investigations 
intended to elucidate the role of copper in central nervous system development and 
disease.  
 
Introduction  
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Copper is an essential nutrient in humans, readily available in the diet and rapidly 
absorbed through the stomach and duodenum into the portal circulation for subsequent 
uptake by the liver. When incorporated into specific cuproenzymes, copper serves as a 
critical cofactor, catalyzing the facile electron transfer reactions required for cellular 
respiration, iron oxidation, pigment formation, neurotransmitter biosynthesis, antioxidant 
defense, peptide amidation, and connective tissue formation (Balamurugan and 
Schaffner, 2006). The liver serves as the predominant organ of copper storage and the 
only physiological mechanism of copper elimination is through excretion into the bile. 
Hepatic copper stores are easily depleted if copper intake is impaired by dietary copper 
deficiency or malabsorption and thus copper deficiency can develop under such 
circumstances (Schilsky and Fink, 2006). Although loss of cuproenzyme function 
accounts for the signs and symptoms of copper deficiency, there are several clinical 
findings in copper deficient patients that are not readily attributable to loss of activity of 
known enzymes, suggesting either novel functions for known cuproenzymes, the 
presence of as yet unidentified enzymes or unique physiological roles for copper.  
 
Physiology of copper deficiency 
Copper can enter cells via Ctr1, a high affinity polytopic membrane transport 
protein found in most tissues. Previous studies in a mouse model of Ctr1 deficiency 
revealed a critical role for this protein in embryonic development but early lethality 
precluded definitive analysis of the role of Ctr1 in copper physiology. The Thiele group 
has recently addressed this issue through the generation of intestinal epithelial cell-
specific Ctr1 knockout mice. These mice are profoundly copper deficient and exhibit 
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striking neonatal defects in copper accumulation in most tissues. By a few weeks of age 
these mice demonstrate severe cardiac hypertrophy, marked growth impairment and 
increased mortality (Nose et al., 2006a). These defects can be overcome by 
administration of parenteral copper treatment, demonstrating the essential role of Ctr1 in 
intestinal copper uptake critical for early postnatal development in the mouse. These 
findings are supported by recent studies in suckling mice from copper-adequate or 
deficient dams that reveal that Ctr1 expression is increased in the intestine following 
perinatal copper deficiency (Kuo et al., 2006). Although the mechanisms of increased 
Ctr1 expression have not yet been determined, these findings are consistent with a critical 
role for this transporter in intestinal copper acquisition. These studies of Ctr1 are critical 
to our understanding of human copper deficiency and strongly suggest that this 
transporter is required for apical membrane enterocyte copper uptake in the human 
intestine. The 6-angstrom projection structure of human Ctr1 based upon electron 
crystallography of two dimensional protein crystals in a native phospholipid barrier 
reveals the formation of a putative pore for metal ions at the interface of three identical 
subunits and reveals a novel architecture not previously described for other transport 
proteins (Aller and Unger, 2006). This protein structure is based upon a Ctr1 trimer and is 
structurally most closely related to channel proteins, suggesting a novel mechanism for 
copper entry across membranes (Nose et al., 2006b). Understanding the precise 
mechanisms by which Ctr1 transports copper will be critical for our understanding of 
acquired copper deficiency in adults where functions of environmental dietary factors 
such as zinc may directly interact with Ctr1 and thus disrupt intestinal copper uptake. 
Such knowledge may also be critical in the design of therapeutics such as cis-platin 
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compounds that utilize this transporter for cellular uptake (Nose et al., 2006b). Inherited 
polymorphismin the gene encoding human Ctr1 might be predicted to account for 
variations in copper uptake amongst individuals and here again detailed structural 
information may be of great value in interpreting the molecular outcome of these genetic 
variants. 
 
Acquired copper deficiency in adults 
Acquired copper deficiency in adults may occur following increased zinc intake, 
long-term parenteral nutrition or malabsorption from a variety of causes. The most 
commonly reported manifestations of copper deficiency are hematological and may 
include neutropenia, thrombocytopenia and anemia. Most recently increasing numbers of 
patients have been identified with acquired copper deficiency of unknown etiology. 
Harless and colleagues (Harless et al., 2006) describe two healthy young women with 
copper deficiency of unclear cause, which resolved after copper supplementation. The 
authors suggest that dietary factors, including soft drink consumption, may have been 
involved and that the problem may be more widespread than is currently realized, a 
concept supported by similar case reports from multiple institutions in the past few years. 
Accompanying such reports has been the recognition of a syndrome of adult-onset copper 
deficiency with neurological manifestations (Kumar et al., 2004). Affected individuals 
present with sensory ataxia, hyperreflexia and a spastic gait similar to the progressive 
ataxic myelopathy in goats and sheep raised on copper-deficient diets. If detected early, 
copper supplementation always resolves the hematological manifestations and may 
prevent further neurological deterioration. Neurologic recovery may, however, be slow 
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and preferentially involves the sensory symptoms. Recent studies in three copperdeficient 
adults, two of whom were referred with a presumptive diagnosis of amyotrophic lateral 
sclerosis, revealed progressive asymmetric weakness and electrodiagnostic findings of 
proximal and distal denervation suggestive of lower motor neuron disease. Copper 
replacement resulted in improvement in this weakness suggesting that the neurologic 
spectrum of copper deficiency should include lower motor neuron disease (Weihl and 
Lopate, 2006). The neurologic signs and symptoms of copper deficiency may be present 
without the hematological manifestations and relapse has been reported on adequate 
copper supplementation (Prodan et al., 2006), suggesting caution in both the diagnosis 
and long-term follow-up of patients with acquired copper deficiency. While this 
syndrome has been reported following recognized causes of copper deficiency including 
zinc ingestion (Willis et al., 2005) and malabsorption (Everett et al., 2006; Tan et al., 
2006), it would appear that the majority of cases occur without any identifiable cause. 
Increased serum concentrations of zinc have been reported in several patients even in the 
absence of exogenous zinc ingestion, but this is not a universal observation and the 
significance of this finding is unknown. Magnetic resonance imaging reveals increased 
T2 signal in the dorsal midline cervical and thoracic cord that is reversible with 
normalization of serum copper (Kumar et al., 2006). Taken together, these clinical and 
radiologic findings are very similar to the subacute combined degeneration reported in 
patients with vitamin B12 deficiency. Consistent with this finding, a pilot study reports 
undiagnosed copper deficiency in a number of elderly patients with vitamin B12 
deficiency, implying a role for copper in the pathogenesis of this disease (Prodan et al., 
2006). 
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Developmental copper deficiency and Menkes disease 
Clinical and experimental data indicate that copper is essential for normal 
development as copper deficiency during pregnancy results in neurologic impairment and 
defects in organogenesis in multiple tissues. Menkes disease, a fatal neurodegenerative 
disorder resulting in seizures, hypotonia, and failure to thrive, is due to inherited loss-of-
function mutations in the gene encoding the copper-transporting ATPase atp7a. Although 
affected patients exhibit signs and symptoms of copper deficiency, the mechanisms 
resulting in neurologic disease remain unknown. To elucidate the mechanisms for these 
defects a chemical genetic screen was undertaken in zebrafish, revealing a role for copper 
in notochord formation and demonstrating a hierarchy of copper metabolism within the 
developing embryo (Mendelsohn et al., 2006). A genetic screen for embryos phenocopied 
by copper deficiency, identified calamity, a mutant defective in the zebrafish ortholog of 
atp7a. The availability of a zebrafish model of Menkes disease permits a precise 
characterization of the genesis of the developmental abnormalities associated with this 
disorder and permits high-throughput chemical suppression screens for compounds of 
immediate clinical relevance that restore cuproenzyme function in the setting of atp7a 
deficiency. Of direct relevance to our understanding of copper deficiency in humans, the 
gene dosage of atp7a in these studies was found to determine the sensitivity to copper 
deprivation, revealing that the developmental hierarchy of copper metabolism is informed 
by specific genetic factors (Merchant and Sagasti, 2006). These data suggest the 
intriguing possibility that suboptimal copper availability due either to dietary factors or 
genetic variation may contribute to structural birth defects and suggest the need for a 
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more critical analysis of copper deficiency in the setting of specific, isolated phenotypes 
in the newborn infant.  
Studies of a loss-of-function allele of DmATP7, the Drosophila orthologue of the 
Menkes and Wilson genes, reveal that copper is essential in embryogenesis in this 
organism, as well as early larval development and adult pigmentation. The data also 
suggest the possibility of novel functions for this transporter in the developing larva that 
may be relevant to our understanding of human copper deficiency (Norgate et al., 2006). 
Characterization of the neurodevelopmental expression and localization of atp7a in the 
murine brain reveals that this transporter is most abundant in the early postnatal period 
and increases in specific regions localized to CA2 hippocampal pyramidal and cerebellar 
Purkinje neurons (Niciu et al., 2006). In this study, atpt7a was detected in the axons of 
postnatal, but not adult, optic nerve suggesting unique stage-specific roles for this 
protein. The precisely regulated neurodevelopmental expression of atp7a observed in 
these studies provides an important histological correlate for the limited therapeutic 
window in patients with Menkes disease. Analysis of atp7a expression by this same 
group within the developing olfactory system suggests a role for this transporter in axon 
extension, a finding that could account for a component of the neurodegeneration in 
Menkes disease (El Meskini et al., 2005). Recent analysis of global changes in gene 
expression in the brain tissue from patients with Menkes disease reveals downregulation 
of genes involved in myelination, energy metabolism, and translation and may offer 
further insight into the pathogenesis of copper deficiency within the developing brain 
(Liu et al., 2005).  
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Cell biological analysis within hippocampal neurons reveals a critical role for 
atp7a in the availability of an N-methyl-D-aspartate (NMDA) receptor-dependent, 
releasable pool of copper, demonstrating a unique mechanism linking copper homeostasis 
and neuronal activation within the central nervous system (Schlief et al., 2005). These 
findings suggest a role for copper in activity-dependent modulation of synaptic activity 
and in support of this hypothesis, copper chelation exacerbates NMDAmediated 
excitotoxic cell death in primary hippocampal neurons, whereas the addition of copper is 
protective (Schlief et al., 2006). This protective effect of copper depends on endogenous 
nitric oxide production in hippocampal neurons, demonstrating in-vivo links among 
neuroprotection, copper metabolism, and nitrosylation. Atp7a is required for these 
copper-dependent effects because hippocampal neurons isolated from a murine model of 
Menkes disease reveal a marked sensitivity to endogenous glutamate-mediated NMDA 
receptor-dependent excitotoxicity in vitro, and mild hypoxic/ischemic insult to these mice 
in vivo results in significantly increased neuronal injury. Taken together, these data 
reveal a unique connection between copper homeostasis and NMDA receptor activity that 
is of broad relevance to the processes of synaptic plasticity and excitotoxic cell death. 
The observation that copper deficiency exacerbates excitotoxic cell death reveals a 
unique paradigm for neuronal injury in patients with Menkes disease and suggests a 
novel approach to the treatment of intractable seizures in such patients via blockade of 
excitatory neuronal pathways (Schlief and Gitlin, 2006).  
Patients with Menkes disease reveal many of the classic signs and symptoms of 
copper deficiency including marked connective tissue abnormalities secondary to 
impaired activity of copper-dependent lysyl oxidases. Recent reports reveal that 
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metaphyseal dysplasia and fractures in such patients may be initially confused with child 
abuse (Bacopoulou et al., 2006). Unusual clinical findings have also recently been 
reported that include severe brachial artery aneurysms (Godwin et al., 2006) and bilateral 
panlobular emphysema and pulmonary arterial hypoplasia (Grange et al., 2005) also due 
to copperdependent impairment in connective tissue biosynthesis and cross-linking. 
While Menkes disease is the only well defined genetic cause of copper deficiency during 
human development, the recent report of a 4-month-old infant presenting with congenital 
cataract, severe muscular hypotonia, developmental delay, sensorineural hearing loss and 
cytochrome c oxidase deficiency with repeatedly low copper and ceruloplasmin levels 
suggests the possibility of additional such disorders. Consistent with this idea, the family 
history in this case revealed parental consanguinity and although genetic analysis of all 
known copper genes was normal, copper histidine supplementation resulted in a 
remarkable improvement of clinical symptoms, suggesting as yet unidentified proteins 
controlling copper homeostasis (Horvath et al., 2005).  
Intractable seizures are a universal feature in almost all patients with Menkes 
disease and a recent analysis in affected children with prolonged survival defined three 
stages of epilepsy development that include early focal status, followed by infantile 
spasms and subsequent myoclonic and multifocal epilepsy after 2 years of life (Bahi-
Buisson et al., 2006). These clinical observations may have relevance for the 
development of treatment optimization for the severe copper deficiency observed in 
Menkes disease. Iinuma and colleagues (Munakata et al., 2005) used proton magnetic 
resonance spectroscopy to examine the metabolic changes in the brain of a boy with 
Menkes disease treated with parenteral copper histidine supplementation from 5 months 
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of age. Therapy initiated after the critical period still improved the neuronal metabolism, 
suggesting that some copper was delivered to neurons despite the fact that brain atrophy, 
impaired myelination, and severe neurological symptoms were largely unaffected. In this 
case and another recent report (Olivares et al., 2006) the authors hypothesize that some 
correlation exists between genotype and clinical outcome after copper histidine therapy, 
although this remains a very poorly understood clinical issue. The Kaler group at the US 
National Institutes of Health has had considerable experience with this treatment 
approach and in a thoughtful review of their experience suggest that in light of the limited 
clinical benefits and potential risks, the decision whether or not to offer copper-
replacement treatment to symptomatic Menkes patients represents an ethical challenge 
best made in each case in consultation with the patient’s parents (Sheela et al., 2005). 
While not advancing our knowledge of treatment mechanisms, this approach is welcome 
and critical to the appropriate care of the family in the circumstances of such a 
devastating diagnosis. 
 
Mitochondrial copper and Sco2 
Under physiological circumstances, the availability of free intracellular copper is 
restricted, and therefore following uptake by Ctr1 copper is bound to a family of proteins 
termed metallochaperones that function to deliver this metal to specific pathways, 
protecting against intracellular copper chelation (Culotta et al., 2006). Copper trafficking 
to the mitochondria is necessary for the proper metallation of cytochrome c oxidase and 
requires the metallochaperones Cox17, Sco1 and Sco2 (Cobine et al., 2006b). As the 
copper-binding subunits of cytochrome c oxidase are encoded by the mitochondrial 
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genome, copper insertion into this protein must occur within this organelle. Consistent 
with a role for these chaperones in cytochrome c oxidase function, inherited deficiency of 
Sco2 results in a fatal encephalocardiomyopathy from impaired respiratory chain function 
(Bohm et al., 2006). Interestingly, a recent report examining patient and parental 
genotypes identified a child with hemizygosity for the common Sco2 missense mutation 
E140K, a finding with important implications for genetic counseling (Leary et al., 2006). 
The relevance of these Sco2 mutations to copper deficiency has recently become more 
apparent with the observation that a mitochondrial matrix copper pool serves as the 
source of copper for cytochrome c oxidase metallation (Cobine et al., 2006a). Most 
interestingly, this process is dependent upon a unique mitochondrial matrix copper ligand 
that may serve as a sensor of copper homeostasis within cells. 
Although the identity of this mitochondrial matrix copper ligand has not yet been 
determined, this finding is of potential broad significance in our understanding of the 
mechanisms of cellular copper homeostasis and the pathogenesis of neuronal injury in 
copper deficiency. This concept is underscored by recent studies that identify Sco2 as a 
critical downstream mediator between the utilization of respiratory and glycolytic 
pathways in cells (Matoba et al., 2006). In this work, p53, a gene frequently mutated in 
cancer, was shown to regulate Sco2 expression. Furthermore, disruption of the Sco2 gene 
in cancer cells with wild-type p53 shifted metabolism toward glycolysis analogous to that 
observed in p53-deficient cells. This metabolic switch to glycolysis, commonly known as 
the Warburg effect, is proposed to provide a significant growth advantage to cancer cells, 
permitting proliferation and possibly promoting invasive characteristics (Assaily and 
Benchimol, 2006; Kruse and Gu, 2006). The finding that Sco2 is a direct metabolic target 
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of p53 reveals an essential and previously unappreciated role for copper in the regulation 
of cellular energy metabolism. Although still in the early stages, such observations 
suggest novel mechanisms for neuronal injury in copper deficiency directly related to the 
mitochondrial regulation of aerobic respiration, energy production and metabolism. 
Conclusion 
Copper deficiency remains an important, albeit uncommon clinical problem. 
Clinical and experimental studies in affected patients continue to reveal new insights into 
the fundamental roles of copper in cellular biochemistry. Exciting new findings regarding 
the role of copper in synaptic plasticity and excitotoxicity offer new therapeutic 
approaches and suggest unique functions of copper in neurobiology. Lastly, observations 
on the role of copper and Sco2 in mitochondrial biology may herald new insights into the 
role of copper in mitochondrial biology, energy homeostasis and neurodegenerative 
disease. 
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Abstract 
Copper and iron are transition elements essential for life. These metals are required to 
maintain the brain’s biochemistry such that deficiency or excess of either copper or iron 
results in central nervous system disease. This review focuses on the inherited disorders 
in humans that directly affect copper or iron homeostasis in the brain. Elucidation of the 
molecular genetic basis of these rare disorders has provided insight into the mechanisms 
of copper and iron acquisition, trafficking, storage, and excretion in the brain. This 
knowledge permits a greater understanding of copper and iron roles in neurobiology and 
neurologic disease and may allow for the development of therapeutic approaches where 
aberrant metal homeostasis is implicated in disease pathogenesis.    
Introduction  
Copper and iron function as cofactors in specific proteins, catalyzing electron 
transfer reactions required for cellular metabolism and binding inorganic ions (e.g., 
oxygen) that serve as substrates for this biochemistry (Andrews and Schmidt, 2007; 
Balamurugan and Schaffner, 2006). Deficiency in these metals results in metabolic 
abnormalities due to loss of function of these iron- and copperdependent proteins. Excess 
of these metals can result in the unregulated oxidation of proteins, lipids, and other 
cellular components causing subsequent tissue injury. Thus pathways of copper and iron 
metabolism have evolved to ensure adequate amounts of each metal for cellular survival 
while protecting the organism from the consequences of metal excess. In the past decade, 
elucidation of the genetic basis of many of the inherited copper and iron metabolism 
disorders has begun to provide insight into these pathways, permitting an understanding 
of the mechanisms involved in cellular homeostasis of these metals. 
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The inherited copper and iron metabolism disorders that cause deficiency or 
excess of these metals in the brain result in central nervous system disease (Ponka, 2004; 
Waggoner et al., 1999). Although these disorders reveal that copper and iron homeostasis 
is essential for normal brain function, little is currently known about the mechanisms of 
copper and iron acquisition, trafficking, storage, and excretion within the central nervous 
system. How and where are iron and copper stored in the brain and under which 
circumstances do these metals accumulate? How do cells in the brain acquire these 
metals when needed? Why is iron deficiency in utero associated with significant long-
term cognitive impairment? How are the uptake and excretion of these metals regulated 
in the brain, and what is the relationship to these processes in systemic circulation? How 
does excess copper accumulation within the brain result in psychiatric disease? Does 
impaired homeostasis of copper or iron contribute to the pathogenesis of common 
neurodegenerative disorders such as Parkinson or Alzheimer disease? One only has to 
view the clinical consequences of accumulation or deficiency of these metals in the 
human brain to appreciate the critical nature of such questions. Mechanistic 
understanding of the human genetic disorders that impair copper or iron homeostasis in 
the brain provides insight into the role of these metals in neurobiology and disease.   
 
COPPER 
Overview 
Copper is required for cellular respiration, iron oxidation, pigment formation, 
neurotransmitter biosynthesis, antioxidant defense, peptide amidation, and connective 
tissue formation (Pena et al., 1999). This metal is essential for central nervous system 
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development, and disruption of copper homeostasis during fetal life leads to perinatal 
mortality, severe growth retardation, and neurodegeneration (Keen et al., 1998). 
Experiments in mice reveal that the developmental timing of perinatal copper deficiency 
influences the severity of neurological outcome, suggesting a critical period for brain 
copper acquisition (Prohaska and Brokate, 2002). Acquired copper deficiency in adults 
results in myelopathy with lower limb spasticity and sensory ataxia due to ascending 
sensory tract dysfunction and neurodegeneration of the dorsal column (Kumar et al., 
2004; Prodan et al., 2006). 
Menkes disease and Wilson disease are the known inherited disorders of copper 
metabolism in humans (Table 1). The essential role of copper in the developing central 
nervous system is evidenced by Menkes disease, during which impaired copper transport 
into and within the developing brain results in demyelination and neurodegeneration 
(Kaler, 1998; Kodama et al., 1999). Brain copper accumulation inWilson disease results 
in dystonia, dysarthria, and other Parkinsonian symptoms, as well as psychiatric 
symptoms of depression, cognitive deterioration, personality change, psychosis, and 
schizophrenia (Ferenci, 2004; Oder et al., 1991). Although the signs and symptoms of 
Menkes and Wilson diseases are distinct, each disorder results from inherited loss-of-
function mutations in genes encoding homologous copper-transporting P-type adenosine 
triphosphatases (Atpases) Atp7a and Atp7b (Figure 1) (Culotta and Gitlin, 2001a).  
Copper Metabolism 
Copper is readily available in the diet and, following absorption through the 
stomach and duodenum, is rapidly removed from the portal circulation by hepatocytes in 
the liver. Biliary excretion is the only physiological mechanism of copper elimination, 
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and at steady state the amount of copper excreted into the bile is equivalent to that 
absorbed from the intestine (Gitlin, 2003). The rate of copper excretion into the bile 
increases promptly in response to an increase in dietary copper, and excess of this metal 
does not occur in the absence of an underlying metabolic defect (Gollan and Deller, 
1973). This aspect of copper homeostasis is critical to the interpretation of any study that 
implicates increases in dietary copper content with neurologic disease (Sparks and 
Schreurs, 2003).  
Ctr1 is a plasma membrane protein essential for early embryonic development 
and intestinal copper uptake (Kuo et al., 2001; Lee et al., 2001; Nose et al., 2006a) 
(Figure 2). Ctr1 is present on endothelial cells of the bloodbrain barrier, and expression 
at this site increases following perinatal copper deficiency (Kuo et al., 2006). These 
observations suggest that copper is transported from the plasma into the brain via Ctr1. 
Intracellular copper metabolism is dependent on the copper transport Atpases, Atp7a and 
Atp7b. One of these Atpases resides in the late Golgi of every cell, delivering copper to 
the secretory pathway for incorporation into cuproenzymes and excretion (Figure 1). In 
the brain, Atp7a is expressed in endothelial cells of the bloodbrain barrier and facilitates 
copper movement across the basolateral membrane into the extravascular space of the 
brain. Atp7a is also ex- pressed within specific populations of neurons in several brain 
regions including the cerebellum and hippocampus (Figure 3). Atp7b is expressed in 
hepatocytes and is required for copper excretion from these cells into the bile. Copper-
dependent trafficking of these Atpases serves as the primary mechanism determining 
intracellular copper homeostasis (Lutsenko and Petris, 2003; Petris et al., 1996) (Figure 
2). 
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Intracellular trafficking of copper also requires proteins termed metallochaperones 
that direct this metal to specific cellular pathways (O'Halloran and Culotta, 2000; Rae et 
al., 1999). These chaperones include Atox1, which delivers copper to the 
coppertransporting Atpases in the late Golgi (Hamza et al., 2001; Hamza et al., 2003), 
CCS, which is required for copper incorporation into cytoplasmic Cu/Zn superoxide 
dismutase (Culotta et al., 2006; Wong et al., 2000), and Cox17, Sco1, and Sco2, which 
deliver copper to mitochondrial cytochrome c oxidase (Hamza and Gitlin, 2002) (Figure 
2). Sco1 and Sco2 also function in a pathway of mitochondrial copper homeostasis 
(Leary et al., 2007). Metallothionein is a cysteine-rich cytoplasmic protein that chelates 
copper and is essential to protect against the toxicity caused by excess copper (Kelly and 
Palmiter, 1996). 
Copper is distributed throughout most regions of the brain and is most abundant 
in the basal ganglia. Studies have detected this metal in the cell bodies of cortical 
pyramidal and cerebellar granular neurons, in the neuropil of the cerebral cortex, in the 
hippocampus and cerebellum, and in synaptic membranes of afferent nerves (Kozma et 
al., 1981; Sato et al., 1994; Trombley and Shepherd, 1996). In some neurons, copper is 
released at the synapse (Brown et al., 1997; Hartter and Barnea, 1988) reaching 
micromolar concentrations (Kardos et al., 1989) that can abrogate long-term potentiation 
in the hippocampus (Doreulee et al., 1997). Copper is an antagonist at N-methyl- D-
aspartate (NMDA) receptors in cultured hippocampal neurons (Vlachova et al., 1996; 
Weiser and Wienrich, 1996), modulating activation of calcium-dependent cascades that 
contribute to synaptic plasticity (Lu et al., 2001). Synaptic NMDA receptor activation 
results in rapid and reversible trafficking of Atp7a in cultured hippocampal neurons in 
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association with copper release, suggesting the presence of a mechanism linking copper 
homeostasis and neuronal activation within the brain (Schlief et al., 2005) (Figure 3). 
Menkes Disease 
Menkes disease is an X-linked disorder characterized by growth failure, brittle 
hair, hypopigmentation, arterial tortuosity, and neuronal degeneration due to loss-of-
function mutations in the gene encoding Atp7a (Chelly et al., 1993; Mercer et al., 1993; 
Vulpe et al., 1993). The pleiotropic features of this disease are the result of impaired 
activity of specific cuproenzymes resulting from impaired Atp7a function (Figure 2). 
The neurologic features are present in early infancy, revealing a critical role for Atp7a 
and copper in neuronal development (Mercer, 1998). Magnetic resonance imaging of the 
brain reveals deficient myelination with cerebellar and cerebral atrophy (Geller et al., 
1997; Leventer et al., 1997), and neuropathologic examination demonstrates focal 
degeneration of the gray matter and neuronal loss most prominent in the hippocampus 
and cerebellum (Barnard et al., 1978; Okeda et al., 1991) (Figure 4). 
Although several of the known cuproenzymes play critical roles in brain 
biochemistry, the mechanisms of neurodegeneration in Menkes disease are unknown and 
not explained by impaired activity of any of these enzymes (Table 2). Studies in a murine 
model of Menkes disease suggest a role for Atp7a and copper in axon extension and 
synaptogenesis during development (El Meskini et al., 2005). Atp7a mediates the 
availability of an NMDA receptor–dependent, releasable pool of copper in hippocampal 
neurons (Schlief et al., 2005), and the absence of Atp7a activity in Menkes disease 
markedly accentuates NMDA receptor–mediated excitotoxicity in these neurons (Schlief 
et al., 2006). These data suggest a model whereby loss of Atp7a contributes to both 
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seizures and neuronal degeneration in affected patients and raise the possibility of 
therapeutic approaches based on NMDA receptor blockade (Hardingham and Bading, 
2003; Schlief et al., 2006). 
Systemic copper treatment is not effective in patients with Menkes disease 
because copper transport into the brain is dependent on Atp7a. Rare patients with some 
residual Atp7a activity have less central nervous system pathology despite significant 
systemic disease (Moller et al., 2000) and when treated with copper evidence 
neurodevelopmental improvement (Christodoulou et al., 1998; Kaler et al., 1995). This 
clinical observation reveals a hierarchy of copper distribution preferential to the brain 
under circumstances of limited copper availability, a concept supported by recent 
observations in a zebrafish model of Menkes disease (Mendelsohn et al., 2006). The 
mechanisms of this hierarchy are unclear but this process illustrates copper’s essential 
role in brain development. 
Wilson Disease 
Wilson disease is an autosomal recessive disorder resulting in hepatic cirrhosis 
and progressive basal ganglia degeneration due to loss-of-function mutations in the gene 
encoding the copper-transporter Atp7b (Bull et al., 1993; Tanzi et al., 1993; Yamaguchi 
et al., 1993). The resulting impairment in biliary copper excretion leads to hepatocyte 
copper accumulation, copper-mediated liver damage, activation of cell-death pathways, 
leakage of copper into the plasma, and eventual copper overload in all tissues (Figure 4) 
(Gitlin, 2003; Tao and Gitlin, 2003). Although Atp7b is expressed in some regions of the 
brain, in Wilson disease copper overload in extrahepatic tissues is due to excess 
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accumulation from the plasma following liver injury because this is entirely reversed 
following liver transplantation (Emre et al., 2001; Schumacher et al., 2001). 
Ceruloplasmin is an essential ferroxidase that contains greater than 95% of the 
copper present in plasma. This protein is synthesized in hepatocytes and secreted into the 
plasma following the incorporation of six copper atoms in the late secretory pathway. In 
Wilson disease, loss of function of Atp7b results in synthesis of apoceruloplasmin that is 
rapidly degraded in the plasma (Figure 5). As a result, the serum ceruloplasmin 
concentration is a useful diagnostic indicator ofWilson disease (Hellman and Gitlin, 
2002).  
Almost half of all patients with Wilson disease present with signs and symptoms 
of neuropsychiatric illness (Gollan and Gollan, 1998). Although such neurological 
features may initially be subtle, without chelation patients will progress to severe 
Parkinsonian symptoms, consistent with the neuropathologic findings of basal ganglia 
copper accumulation and neurodegeneration (Oder et al., 1991). Neurodegeneration in 
Wilson disease results directly from copper accumulation, but the precise mechanisms of 
cellular injury are unknown. Psychiatric symptoms are also common and range from 
behavioral problems to psychosis (Dening, 1991). These abnormalities, although without 
neuropathologic correlates, are clearly the result of brain copper accumulation because 
prompt improvement is observed upon treatment with oral chelating agents to restore 
copper homeostasis. The reversible nature of many of these psychiatric symptoms is 
consistent with the concept that copper can modulate synaptic function (Schlief and 
Gitlin, 2006) and suggests novel avenues for investigation in common psychiatric 
disorders. 
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IRON 
Overview 
Iron is required as a cofactor in central nervous system metabolic processes 
including oxidative phosphorylation, neurotransmitter production, nitric oxide 
metabolism, and oxygen transport (Ponka, 1999). The observation that brain iron content 
is increased in patients with Parkinson disease and other neurodegenerative disorders has 
created significant interest in the possibility that disturbances of brain iron homeostasis 
may contribute to the pathogenesis of these diseases (Thomas and Jankovic, 2004). 
Although numerous clinical and experimental studies have attempted to address this 
issue, a causative role for impaired iron homeostasis has yet to be established in these 
more common neurodegenerative diseases. Nevertheless, interest in this neuropathology 
has focused increased attention on elucidating the mechanisms of brain iron homeostasis 
and on defining iron’s role in neurologic disease. 
The inherited diseases of iron metabolism are more common and more numerous 
than those of copper, and the genetic basis of many of these disorders has been 
characterized (Andrews, 2002). Although many of the proteins shown to be essential for 
systemic iron homeostasis are expressed within the brain (Wu et al., 2004; Zecca et al., 
2004), genetic disorders resulting in loss of function of these proteins rarely result in 
either brain iron overload or deficiency or neurologic disease. For example, although 
ferroportin is abundantly expressed in the brain microvasculature and is the only known 
cellular iron exporter, patients with mutations that impair this protein’s function have no 
evidence of brain iron accumulation (Pietrangelo, 2006a). These observations suggest the 
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presence of unique mechanisms regulating iron metabolism within the central nervous 
system. 
 
Iron Metabolism 
Genetic analysis of the inherited iron metabolism disorders has identified many of 
the proteins necessary for systemic iron homeostasis (Hentze et al., 2004; Pietrangelo, 
2006b) (Figure 6). Ferrous iron (Fe2+) is taken up into cells by the divalent membrane 
transporter DMT1, whereas ferric iron (Fe3+) enters cells via endocytosis of the 
transferrin receptor following binding to transferrin (Andrews and Schmidt, 2007). The 
most compelling feature of systemic iron homeostasis is that iron requirements far exceed 
the gastrointestinal absorption capacity, and thus almost all the iron utilized each day is 
continuously recycled from internal stores (Koury and Ponka, 2004) (Figure 7). Central 
to this process is the hepatocyte-derived peptide hepcidin, which regulates iron 
availability in response to hypoxia, inflammation, erythropoietic needs, and iron stores 
(Nemeth and Ganz, 2006). Hepcidin binds to and induces the endocytosis and turnover of 
the plasma membrane iron exporter ferroportin, which is the primary determinant of 
gastrointestinal iron absorption and iron release from reticuloendothelial stores (Nemeth 
et al., 2004). Ceruloplasmin plays a critical role in this process by establishing a rate of 
plasma iron oxidation sufficient for the continued release of this metal from the storage 
sites (Harris et al., 1998) (Figure 7). 
Iron is taken up into the brain from the plasma via transferrin receptor–mediated 
endocytosis in the brain capillaries and returned to circulation via absorption of 
cerebrospinal fluid (Moos et al., 2006). Brain iron accounts for less than 2% of the total 
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body iron content and varies greatly in amount and concentration depending on the 
specific region of the brain. The concentration of iron in the brain is greatest in the basal 
ganglia where it is equivalent to that found in the liver, suggesting a role in brain iron 
storage and distribution (Haacke et al., 2005). Iron is widely distributed in all cell types 
within the central nervous system but is abundant especially in astrocytes, supporting the 
idea that these cells and other types of glia function in iron storage and regulation. 
Iron requirements in the brain are much greater than the observed rate of iron 
uptake into this tissue (Bradbury, 1997). This finding suggests most brain iron used each 
day is derived from recycling behind the bloodbrain barrier analogous to what occurs in 
the periphery (Figure 7). This mechanism would protect the brain from the effects of 
systemic iron overload or deficiency and is supported by observations that disturbances 
of systemic iron homeostasis exhibit minimal effects on central nervous system iron 
content or metabolism (Moos and Morgan, 2004). The rate of brain iron uptake is greatest 
during fetal life and postnatal iron repletion is ineffective to correct the cognitive defects 
arising from iron deficiency in utero; this concept indicates that following birth recycling, 
rather than uptake from the circulation, is the major iron source for brain function (Lozoff 
et al., 2006). Existence of this brain iron cycle has critical implications for interpreting 
any finding of brain iron accumulation in disease. The inherited disorders 
aceruloplasminemia and neuroferritinopathy support the concept of a brain iron cycle and 
demonstrate that dysregulation of brain iron homeostasis can be a primary cause of 
neurodegeneration (Ponka, 2004) (Table 3). 
Aceruloplasminemia 
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Aceruloplasminemia is an autosomal recessive disorder of iron homeostasis 
caused by loss-of-function mutations in the ceruloplasmin gene (Harris et al., 1995; 
Yoshida et al., 1995). Patients have absent serum ceruloplasmin, decreased serum iron, 
elevated serum ferritin, anemia, and insulin-dependent diabetes mellitus (Gitlin, 1998; 
Nittis and Gitlin, 2002). Despite these systemic features, most patients present with 
progressive dementia, dysarthria, and dystonia secondary to basal ganglia iron 
accumulation (Logan et al., 1994; Miyajima et al., 1987; Morita et al., 1995). The 
neurologic disease in aceruloplasminemia is always associated with increased brain iron 
as detected by magnetic resonance imaging or autopsy (Kono and Miyajima, 2006). 
Histological findings from affected brain regions include neuronal cell loss, abnormal 
astrocyte architecture, and excess iron deposition in glia and neurons (Kaneko et al., 
2002; Morita et al., 1995; Oide et al., 2006) (Figure 4). 
The absence of ceruloplasmin results in the slow accumulation of iron in the 
reticuloendothelial cells where this metal is normally stored and then mobilized for 
recycling (Harris et al., 1999; Patel et al., 2002) (Figure 7). This mechanism of systemic 
iron accumulation also occurs in patients with dominant-negative mutations in the gene 
encoding the iron exporter ferroportin (De Domenico et al., 2006). Loss of ceruloplasmin 
also results in increased nontransferrinbound iron that rapidly accumulates in the liver, 
pancreas, and other tissues following removal from the plasma by DMT1 (Andrews, 
2002; Hentze et al., 2004) (Figure 7). This mechanism of tissue iron accumulation also 
occurs in atransferrinemia, where the absence of serum transferrin increases the relative 
amount of nontransferrin-bound plasma iron (Craven et al., 1987); in HFE 
hemochromatosis, where excess iron absorption elevates nontransferrin-bound plasma 
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iron (Andrews, 2002); in the thalassemias and other forms of secondary iron overload, 
where transfusiondependency elevates nontransferrin-bound plasma iron (Pietrangelo, 
2006b); and in hemochromatosis, owing to loss-of-function mutations in ferroportin that 
impair hepcidin regulation inappropriately increasing nontransferrin-bound iron (De 
Domenico et al., 2006). 
Although these disorders of iron metabolism share common mechanisms of tissue 
iron overload, accumulation of iron in the brain is unique to aceruloplasminemia. The 
absence of brain iron accumulation in other diseases with increased nontransferrinbound 
plasma iron supports the idea that brain iron accumulation in aceruloplasminemia results 
directly from impaired iron homeostasis within the central nervous system. Consistent 
with this concept, ceruloplasmin is synthesized in astrocytes (Klomp et al., 1996; Klomp 
and Gitlin, 1996) as a glycophosphatidylinositol-linked isoform (Jeong and David, 2003; 
Patel et al., 2000), suggesting that this membrane-bound ferroxidase facilitates the rate of 
iron release from storage cells within the central nervous system. Ceruloplasmin is one of 
very few proteins established as playing a critical role in brain iron homeostasis. 
Neuroferritinopathy 
Ferritin is a ubiquitously expressed cytoplasmic iron storage protein consisting of 
heavy and light chains encoded on separate genes (Figure 6). Iron-dependent 
translational regulation of this protein by the cytosolic iron regulatory proteins Irp1 and 
Irp2 ensures that ferritin is a readily available source of intracellular iron in all cells 
including neurons and glia (Rouault, 2006). Neuroferritinopathy, an autosomal dominant 
extrapyramidal disease resulting from mutations in the gene encoding the light chain of 
ferritin, has revealed a primary role for ferritin in brain iron homeostasis (Curtis et al., 
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2001; Maciel et al., 2005; Mancuso et al., 2005; Vidal et al., 2004). Pathological 
examination of affected patients reveals cavitary degeneration in the basal ganglia nuclei, 
neuronal loss, and iron and ferritin in both extracellular and cytoplasmic inclusion bodies 
of microglia. The autosomal dominant inheritance and the multimeric structure of ferritin 
suggest that these mutations impair ferritin assembly resulting in loss of iron storage 
capacity within brain cells and subsequent iron-mediated cell injury (Levi et al., 2005). 
Although there are some phenotype-genotype correlations specific to each light chain 
mutation, all patients with neuroferritinopathy evidence dystonia in association with basal 
ganglia iron accumulation (Chinnery et al., 2007). 
Patients with neuroferritinopathy express the ferritin light chain mutation in all 
cells yet evidence no abnormalities in systemic iron homeostasis with the exception of 
decreased serum ferritin (Chinnery et al., 2007). This finding suggests either a unique 
role for the ferritin light chain in some cell types within the brain or a greater sensitivity 
of these cells to this form of iron-dependent injury. Although the mechanism of 
neurodegeneration in neuroferritinopathy is unknown, the similar pathology to 
aceruloplasminemia suggests a role for ferritin in the brain iron cycle and implies a 
common iron-dependent mechanism of neurodegeneration in these two diseases (Figure 
7). Recent studies in aceruloplasminemia suggest that neuronal loss in this disease arises 
from iron deficiency secondary to impaired iron movement from astrocytes within the 
brain iron cycle (Jeong and David, 2006). Support for a similar mechanism in 
neuroferritinopathy comes from a murine model of Irp2 deficiency that impairs ferritin 
regulation, results in iron accumulation within oligodendrocytes, and leads to 
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neurodegeneration most likely from secondary neuronal iron deficiency (LaVaute et al., 
2001). 
Friedreich’s Ataxia 
Friedreich’s ataxia is an autosomal recessive disorder characterized by sensory 
neuron, cerebellar, and cardiomyocyte degeneration (Durr et al., 1996) due to loss of 
function of frataxin, a mitochondrial protein involved in inorganic iron-sulfur (Fe/S) 
cluster biogenesis (Babcock et al., 1997). Although not specific to the brain, the effect of 
impaired mitochondrial iron homeostasis on neuronal survival in this disease warrants 
mention here. Mitochondrial iron is required for heme biosynthesis and for the generation 
of Fe/S clusters that are prosthetic groups in many essential enzymes (Ajioka et al., 2006; 
Lill and Muhlenhoff, 2006). Iron is imported into mitochondria by mitoferrin, a 
transporter expressed in the inner mitochondrial membrane (Shaw et al., 2006), and exits 
mitochondria largely in the form of Fe/S clusters (Rouault and Tong, 2005). Although 
excess mitochondrial iron is detected in cardiomyocytes and sensory neurons from 
affected patients (Puccio et al., 2001), impairment of heme and Fe/S cluster biosynthesis 
is the likely proximate cause of neurodegeneration in Friedreich’s ataxia (Lill and 
Muhlenhoff, 2006; Voncken et al., 2004). 
Neurodegeneration with Brain Iron Accumulation 
Neurodegeneration with brain iron accumulation describes a heterogeneous group 
of patients with progressive neurodegeneration and iron deposition in the basal ganglia 
(Gregory and Hayflick, 2005; Hayflick et al., 2003). Most of these patients present in 
childhood with dystonia, dysarthria, and pigmentary retinopathy and have autosomal 
recessive, loss-of-function mutations in the gene-encoding mitochondrial pantothenate 
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kinase 2, an essential mitochondrial enzyme involved in coenzyme A biosynthesis 
(Hayflick et al., 2003; Johnson et al., 2004; Zhou et al., 2001). The mechanisms of iron 
accumulation and the role of iron, if any, in the pathogenesis are unknown. However, 
these disorders deserve mention because recent studies reveal mutations in the gene 
encoding a calcium-independent group VI phospholipase A2 in some children with brain 
iron accumulation and neurodegeneration, suggesting a novel link between phospholipid 
and iron metabolism in the brain (Morgan et al., 2006). 
CONCLUSIONS 
The inherited disorders of copper metabolism reveal copper’s essential role in 
brain development and neuropsychiatric disease. The mechanisms of psychiatric disease 
observed in patients with Wilson disease are of particular interest. Chelation is an 
effective therapy in such individuals, indicating copper’s direct role in pathogenesis and 
suggesting avenues for study that may be widely applicable to brain function and mental 
health. Although elucidation of the genetic basis of Menkes andWilson diseases has 
revealed much about the cell biology of copper metabolism, much more needs to be 
learned about the normal mechanisms of copper homeostasis in the brain. In particular, 
the role of the basal ganglia in copper and iron storage and distribution needs further 
study as do the mechanisms of this brain region’s vulnerability to excess copper and iron. 
Recent studies have focused on copper’s role in the pathogenesis of prion-mediated 
encephalopathy and Alzheimer disease, including the proposed treatment of affected 
patients with metal chelating drugs (Bush, 2000; Doraiswamy and Finefrock, 2004; Gaeta 
and Hider, 2005). However, caution is warranted because more knowledge of copper 
homeostasis within the brain and copper’s role in specific neurologic functions is 
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required before any such therapeutic approaches can be thoughtfully undertaken or 
interpreted. 
The discovery of aceruloplasminemia and neuroferritinopathy demonstrates that 
dysregulation of brain iron homeostasis can be a primary cause of neurodegeneration. 
These inherited disorders provide a platform for further mechanistic investigations that 
should reveal new insights into brain iron homeostasis. Nevertheless, absent further 
understanding of the molecular mechanisms of iron homeostasis in the central nervous 
system, investigators currently cannot interpret the significance of iron accumulation in 
the pathogenesis of other neurologic diseases (Lee et al., 2006; Zecca et al., 2004). This 
concept is illustrated by recent studies in aceruloplasminemia that suggest that 
neurodegeneration arises from iron deficiency despite the marked brain iron overload. A 
cautionary tale is also provided by the numerous iron chelator and antioxidant trials 
initiated in patients with Friedreich’s ataxia on the basis of the findings of mitochondrial 
iron accumulation, none of which have any demonstrated clinical benefit in doubleblind 
placebo-controlled trials. These data remind us of the need for critical, mechanistic 
approaches to defining disease pathogenesis when normal physiology remains poorly 
understood. In this regard, attention is given to recent studies identifying a signaling 
cascade in neurons where stimulation of NMDA receptors mediates iron uptake via the 
divalent iron transporter DMT-1. This work provides a physiologic link between neuronal 
function and iron homeostasis and suggests mechanisms linking iron and NMDA 
neurotoxicity that would direct future investigation (Cheah et al., 2006).   
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Table 1 
 
 Wilson Disease Menkes Disease 
Genetics Autosomal recessive X-linked 
 Loss-of-function mutations Loss-of-functions mutations 
 ATP7B gene ATP7A gene 
Presentation Late childhood: liver Early infancy 
 Second-third decated, 
neuropsychiatric 
 
Defect Biliary copper excretion Copper transport across the placenta, brain, and 
gastroinestinal tract 
Pathogenesis Copper accumulation Copper deficiency 
Clinical Cirrhosis, dystonia, dysarthria, 
Parkinsonian tremor, 
psychiatric 
Hypothermia, hypopigmentation, abnormal hair, 
tortuous arteries, intractable seizures, failure to thrive 
Pathology Basal ganglia copper 
accumulation 
Cerebral and cerebellar degeneration 
 Neuronal cell loss Purkinje cell axonal swelling 
  Abnormal arborization 
 
Table 1: The hereditary disorders of copper metabolism 
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Table 2 
 
Enzyme Function Consequences of Loss 
Tyrosinase Melanin formation  Albinism 
Lysyl oxidase Collagen and elastin cross-link 
formation 
Perinatal death: arterial aneurysms, 
diaphragmatic rupture (Hornstra et 
al. 2003) 
Peptidylglycine α-
amidating monooxygenase 
Acitavtion of peptides with α-
terminal glycine 
Embryonic lethality: cardiac failure 
(normal CNS) (Czyzyk et al. 2005) 
Cu/Zn superoxide 
dismutase 
Antioxidant defense (superoxide 
dismutation) 
Impaired pulmonay defenses to 
paraquat; infertility (Ho et al. 1998) 
Ceruloplasmin Ferroxidase Parenchymal iron overload, anemia, 
diabetes, neurodegeneration 
Hephaestin Ferroxidase Impaired iron absorption, anemia 
(Vulpe et al.1999) 
Dopamine-β-hydroxylase Norepinephrine synthesis Impaired sympathetic regulation, 
hypotension, hypoglycemia 
Cytochrome c oxidase Oxidative phosphorylation Encephalopathy, muscle weakness, 
cardiac failure - neonate 
 
Table 2: The cuproenzymes 
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Table 3 
 
 Aceruoloplasminemia Neuroferritinopathy 
Genetics Autosomal recessive Autosomal dominant 
 Loss-of-function mutations Dominant negative 
 Ceruloplasmin gene Ferritin light chain gene 
Presentation Third decade – diabetes Third through sixth decade 
 Fifth decade – neurologic  
Defect Brain iron recycling Brain iron storage 
Pathogenesis Brain iron accumulation 
Systemic iron accumulation 
Brain iron accumulation 
 
Clinical Diabetes, anemia, dementia, 
dystonia, dysarthria 
Dementia, dystonia, dysarthria 
Pathology Iron accumulation in astrocytes Iron accumulation in astrocytes 
 Neuronal cell loss Neuronal loss 
 
Table 3: The hereditary disorders of brain iron metabolism 
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Abstract 
     Although the molecular basis of many inherited metabolic diseases has been defined, 
the availability of effective therapies in such disorders remains problematic. Menkes 
disease is a fatal neurodegenerative disorder due to loss-of-function mutations in the 
ATP7A gene encoding a copper transporting P-type Atpase. To develop novel therapeutic 
approaches in affected patients we have identified a zebrafish model of Menkes disease 
termed calamity that results from splicing defects in the zebrafish orthologue of the 
ATP7A gene. Embryonic recessive lethal mutants have impaired copper homeostasis that 
results in absent melanin pigmentation, impaired notochord formation and hindbrain 
neurodegeneration. In this current study we have attempted to rescue these striking 
phenotypic alterations utilizing a series of antisense morpholino oligonucleotides directed 
against the splice-site junctions of two mutant calamity alleles. Our findings reveal a 
robust and complete correction of the copper-deficient defects of calamity in association 
with the generation of wild-type Menkes protein in all rescued mutants. Interestingly, 
quantitative analysis of atp7a specific transcripts suggests that competitive translational 
regulation may account for the synthesis of wild-type protein in these embryos. This in 
vivo correction of Menkes disease through rescue of aberrant splicing may provide new 
therapeutic options in this fatal disease and illustrates the potential for zebrafish models 
of human genetic disease in the development of treatments based on the principles of 
interactions of synthetic oligonucleotide analogues with mRNA.  
 
Introduction 
     Menkes disease is an inherited metabolic disease due to loss of function mutations in 
the ATP7A gene encoding a P-type Atpase required for copper absorption and 
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homeostasis (Lutsenko et al., 2007; Lutsenko and Petris, 2003). Patients with Menkes 
disease have absent melanin pigmentation, impaired extracellular matrix formation and 
neurodegeneration resulting in intractable seizures, hypotonia, severe failure to thrive and 
death in early infancy (Culotta and Gitlin, 2001b; Kaler, 1998). These pleiotropic 
phenotypes result from loss of activity of essential cuproenzymes within distinct 
subcellular compartments. Treatment with exogenous copper is largely ineffective 
(Sheela et al., 2005) and absent development of directed pharmacotherapy, restoration of 
normal gene function remains the most viable treatment for affected patients. While 
partial correction of a murine model of Menkes disease was demonstrated utilizing a 
human Menkes transgene (Llanos et al., 2006), methods of safely introducing wild-type 
cDNAs into humans have remained elusive.  
     We recently utilized chemical genetics to obtain calamity, a zebrafish model of 
Menkes disease (Mendelsohn et al., 2006). Embryonic mutants reveal a striking 
phenotype with absent melanin pigment, impaired notochord formation and 
neurodegeneration. As several calamity alleles arise from splicing defects in the zebrafish 
orthologue of ATP7A, we reasoned that if normal splicing could be restored sufficient 
wild-type message might be generated to rescue these defects. Furthermore, as previous 
studies of copper nutrition in the zebrafish embryo revealed a hierarchy of temporal and 
dosage-dependent phenotypes (Mendelsohn et al., 2006) unique therapeutic windows 
might allow for long-term correction following transient restoration of wild-type 
expression. Such an approach has broad applicability as many metabolic diseases arise 
from mutations that interfere with normal splicing of pre-mRNA message (Wang and 
Cooper, 2007).  In such cases the threshold of wild-type transcript necessary to restore 
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functional protein may require only a small shift in favor of the wild-type message in 
order to ameliorate the disease.  
     RNA targeting has recently emerged as a potential alternative to more conventional 
approaches in gene therapy (Wood et al., 2007). Antisense oligonucleotides which bind 
to pre-mRNA and sterically alter processing have been used successfully in cell culture to 
demonstrate the utility of this approach (Bruno et al., 2004; Du et al., 2007; Gebski et al., 
2003; Suwanmanee et al., 2002). More recently, in murine models of Duchenne muscular 
dystrophy, systemic delivery of morpholino oligonucleotides has been shown to effect 
partial restoration of protein function on a cellular level in mutant mice (Alter et al., 
2006; Lu et al., 2005; Moulton et al., 2007). A critical factor in such strategies for the 
treatment of human metabolic disorders is the availability of robust disease models that 
permit rapid screening for effective phenotypic rescue. In this current study we have 
utilized such an approach to rescue the phenotype of calamity, demonstrating the 
applicability to complex organisms of several recent cell culture studies using this 
technology in a number of human genetic diseases (Du et al., 2007; Moulton et al., 2007; 
Ugarte et al., 2007).  
 
Results and Discussion 
 Recently, our lab has described the zebrafish mutant calamity (allele vu69) as a 
model of Menkes disease that recapitulates key aspects of the human phenotype 
(Mendelsohn et al., 2006) (Fig. 1A). The defect in calamity
vu69
 is caused by creation of a 
new 3’ splice site resulting in a 7 base-pair insertion into the mRNA (Fig. 1F). The 
subsequent frame-shift creates an early stop codon and loss of greater than 95% of the 
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protein product (Fig. 1 D,E). In the course of continued screening we have identified a 
second allele of calamity, designated gw246. This allele causes an identical phenotype to 
the first and is non-complementary in a standard genetic cross (Fig. 1 B, C).  Cloning of 
the mRNA in this mutant revealed a 12 base-pair in-frame deletion at the 3’ end of exon 
20 which removes 4 amino acids located in the critical and highly conserved ATPase 
domain of Atp7a (Fig. 1F). This deletion at the junction of two exons is due to the 
preferential use of a new 5’ splice site. Interestingly, genomic sequence analysis revealed 
mutation of neither the wild-type 5’ splice site (splice donor) nor creation of a new GT 
splice donor pair; rather, the mutation was five base-pairs downstream from the new 
mutant splice donor. Comparison of the mutant sequence to the previously established 
zebrafish splice donor consensus sequence indicated that a new splice consensus site had 
been formed (Yeo et al., 2004). Given that the mutant displays such a severe phenotype 
we inferred that this new consensus sequence creates a dominant splice donor to the near 
exclusion of the wild-type donor. High-resolution separation of a small PCR product 
from mutant cDNA demonstrates that this is indeed the case (Fig. 2B, lane 1). In this 
mutant, any wild-type splicing that does occur retains a single base change which causes 
a non-conservative amino acid change from Leu to Arg at position 1316 (Fig. 1F). 
Immunoblots with an antibody raised against a C-terminal peptide from zebrafish Atp7a 
revealed near-complete loss of protein product in both vu69 and gw246 (Fig. 1E). This 
lack of protein product in the gw246 allele suggests that there may be an early processing 
defect which causes rapid and early degradation of the protein. 
 The presence of the wild-type splice sites in both alleles of calamity immediately 
caused us to consider the use of morpholinos directed to specific sequences near the 
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mutant splice sites in a bid to “force” wild-type splicing events. There was no data 
available indicating the precise location that would be best suited for accomplishing this 
goal. At the same time, the nature of both alleles provided an ideal system for 
investigating this very question. In the case of gw246 we had two competing splice 
donors sufficiently far apart that we might interfere with one or the other but close 
enough that we might also block both.  
 Design of a series of morpholinos that would “walk” along the exon-intron 
boundary sequence was based on comparison with known consensus sequences (Fig. 
2A). The basic 5' splice site consensus sequence is small and well defined making 
targeting straightforward for the gw246 mutant (Yeo et al., 2004). Wherever a 
morpholino sequence overlapped a mutation, the mutant sequence was used at that base 
pair. The first series of morpholinos were injected at a dose of 1.44 pmol/embryo 
(12ng/embryo) into intercrosses of gw246 heterozygous carriers. At 48hpf embryos were 
examined for phenotypic effects and mutants collected for mRNA extraction and RT-
PCR. The effects on splicing are shown in Fig. 2B. Across the series of morpholinos 
several splice forms were seen. We confirmed that each band is a splice form of atp7a via 
direct sequencing of the RT-PCR product. Several patterns emerged from these 
experiments. First, and most interesting, blocking of the mutant splice donor did indeed 
restore a significant amount of wild-type splice product (lanes e2-e3); however, this was 
not accompanied by a rescue of the phenotype. We surmised that this was due to the 
retention of a single base change caused by the mutation in the final, properly spliced 
transcript which results in the non-conservative L1316R substitution. Such a large change 
in polarity and charge in a highly conserved region of this ATPase might be expected to 
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disrupt function. Consistent with this hypothesis, when we introduced this mutation into 
the wild-type cDNA it resulted in an ATPase that fails to deliver copper to tyrosinase in 
transiently transfected ATP7A-deficient fibroblasts indicating that this mutation results in 
an inactive transporter (Sup. Fig. 1). Alternatively, the mutation may render the protein 
unstable leading to early degradation and subsequent loss of function. 
Second, injection of the series of morpholinos revealed several other weak cryptic 
splice sites all contained within exon 20, immediately 5’ to the mutation (Fig. 2). This is 
most clearly seen when the morpholino overlies both the wild-type and mutant sites 
(lanes e4-e5). There was no evidence of exon skipping induced by any of the 
morpholinos (data not shown). Bands corresponding to inclusion of the entire intron in 
the final product were seen, but we could not totally rule out the possibility of genomic 
contamination of the cDNA as the source of these bands (data not shown).  
Thirdly, the morpholino that accomplished the most robust rescue of mRNA  
splicing (lane e3) overlay the mutant splice site on either side and remained at least 6 
base-pairs 5' to the wild-type GT pair. Moving only four bases in either direction resulted 
in either an increased use of the mutant site or an increase in the upstream cryptic sites 
due to blockage of the wild-type and mutant sites (lane e4-e5). 
Lastly, when the morpholino target sequence was located 3’ to the mutant splice 
donor the mutant again became the dominant splice form (lane e7). Wild-type embryos 
injected with this same morpholino fully displayed the calamity phenotype (Sup. Fig. 
2B). Combined with the RT-PCR data this indicates that when the wild-type 5’ splice site 
is blocked by a morpholino the next most robust cryptic site is the one used in the mutant. 
Injection of wild-type embryos also resulted in the same pattern of splicing illustrating 
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why the mutation is so easily capable of co-opting splicing to the cryptic site in the 
mutant (Sup. Fig. 2A). 
 These specific observations on a trial-and-error approach allow us to propose a set 
of generalities regarding morpholino targeting to an exon-intron junction. First, 
morpholinos targeted within 30bp of an 5’ splice site will have an effect on splicing, even 
if it is subtle. Secondly, in some cases it appears that the magnitude of the effect of the 
morpholino is dependent not only on its distance from the splice site, but also upon the 
general strength of the splice consensus (cf. e1 and e4) and surrounding cryptic sites. 
Thirdly, optimal blocking occurs in two forms: 1) the morpholino is entirely exonic 
except for 2bp overlap with the GT pair (e2 and e5), or 2) the morpholino extends at least 
6 bp on either side of the exon-intron junction. Fourthly, morpholinos can reveal 
unappreciated enhancers and suppressors of specific splicing events located outside of the 
consensus sequence (e10) and can be used to change the hierarchy of cryptic splicing 
events. Validation of these rules will require separate experiments in a different mutant 
with a similar defect and distinct phenotype; however, they do establish a framework 
which can guide further testing. 
 Taken together these results demonstrate the utility of using morpholinos 
to correct aberrant splicing in an embryonic vertebrate in cases where wild-type splice 
donors are not affected. Morpholino e3 strongly rescues the mRNA. Unfortunately we 
did not see a corresponding rescue of the phenotype. That this mutant protein was 
incapable of rescue indicates one of the potential caveats of this system – that the 
retention of a mutation in the rescued mRNA can just as strongly affect the phenotype of 
the organism as the mis-spliced sequence. Promisingly however, it has been estimated 
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that the probability that a random amino acid change would cause protein inactivation is  
around 34% (Guo et al., 2004). Conversely, this would mean that just under two-thirds of 
random amino acid changes will result in functional protein sequence. Together with 
alternate approaches such as forced exon skipping the probability of rescuing any given 
splice mutation with morpholinos remains fairly high. 
 Unlike the gw246 allele, rescue of vu69 would not cause inclusion of the mutated 
base but would fully restore the wild-type sequence without alteration. Also unlike 
gw246 the mutation alters the splice acceptor. The length and placement of consensus 
splicing sequences around the splice acceptor are much less well defined and more 
degenerate making targeting predictions much more cumbersome (Yeo et al., 2004). 
Given the proximity of the vu69 splice acceptor to the polypyrimidine tract, we reasoned 
that directly overlapping the mutant splice acceptor with a morpholino would interfere 
with wild-type splicing. Similarly, we assumed that both mutant and wild-type splice 
acceptors would use the same polypyrimidine tract, making it difficult to preferentially 
target one splice acceptor by direct targeting of the polypyrimidine tract. However, the 
inherent degeneracy of the U2AF recognition sequence might permit a morpholino 
placed nearby to sterically interfere and alter the exact location of binding of the U2AF to 
the polypyrimidine tract (Sickmier et al., 2006). No structural data existed to aid in the 
design of such a morpholino. Therefore, we took a similar approach using a series of 
morpholinos that “walk” across the splice acceptor region but expanded our target area to 
include sequence up to 73 base-pairs 5’ to the mutant acceptor (Fig. 3A). Briefly, 
morpholinos i1 and i2 both caused a more severe phenotype in calamity mutants and 
heterozygotes implying an interference with wild-type splice events (Data not shown). 
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Morpholinos i5 to i7 had no effect on phenotype. Morpholinos i3, i3.5 and i4 caused 
robust rescue of the phenotype of mutant calamity embryos (Fig. 3B-G). Melanin 
pigmentation was restored and the notochord did not contain any discernible defects 
compared with calamity mutant embryos. The rescue was seen in 100% of the mutant 
embryos with all injected mutants containing at least a few melanocytes and 95% having 
greater than 20; no injected mutant embryo had a discernable notochord defect when 
scored at 48 hpf (Fig. 3H). The rescue effect was still clearly visible at 6 days post 
fertilization when about 75% of the uninjected calamity embryos were either dead or 
dysmorphic (Fig. 3I) compared with nearly normal looking rescued embryos (Fig. 3J). 
Lowering the dose of the morpholino resulted in similar pigmentation with intermediate 
notochord defects consistent with previous observations on the developmental hierarchy 
of copper metabolism that revealed a critical threshold of lysyl oxidase activity necessary 
for normal notochord development (data not shown) (Gansner et al., 2007b; Mendelsohn 
et al., 2006). Sequencing of genomic DNA confirmed that the rescued embryos were 
indeed mutant (Data not shown). 
As the mutant embryos had clear phenotypic rescue we wanted to confirm that 
this was the result of restored protein expression. Immunoblot analysis of injected and 
rescued mutants with a zebrafish Atp7a-specific antibody shows the restoration of full-
length, wild-type protein in the rescued embryos compared with no visible protein in 
uninjected mutants (Fig. 4A). To our surprise however, this did not correspond with an 
increase in wild-type splice products as measured via qRT-PCR . Only three consistent 
patterns emerged from these experiments. The first is the presence of a small amount of 
amplifiable wild-type transcript in all of the mutants, consistent with the presence of a 
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wild-type band when end-point RT-PCR products are run on a polyacrylamide gel (Fig. 
4C and Sup. Fig. 3B,C). The second is that there is decreased total atp7a transcript in the 
mutants probably due to nonsense-mediated decay of mutant transcripts (Sup. Fig. 3D). 
The third is that there is a significant reduction of mutant transcript in the injected 
embryos. The most likely explanation for this reduction is the shifting of this transcript to 
a third splice form, which is corroborated by the RT-PCR gel analysis showing a third 
splice form containing an 800bp intronic insertion due to the use of a cryptic 3’ splice site 
within the intron (Fig. 4C). Sequence analysis of the alternate splice form indicates a 
frame shift and early stop codon, analogous to the original mutation. It is important to 
note that as the antibody used for immunoblot recognizes the C-terminus of the wild-type 
zebrafish protein, the identification of full-length protein will only occur when wild-type 
transcripts are present.  
Both the reduction in mutant transcript as well as the lack of any increase in wild-
type transcript levels as measured by qRT-PCR were consistent across three embryo 
ages, 12, 24, and 48 hours post-fertilization (data not shown) indicating that there is not 
an early correction of splicing that decreases as the morpholino is diluted during 
development. The lack of a measurable substantial increase in wild-type transcript in 
these studies could simply reflect the limits of quantitation for the threshold necessary to 
result in rescue. If this is the case, then it suggests that only small changes in wild-type 
mRNA can result in significant phenotypic improvement on an organismal level, at least 
in the case of Menkes disease.  Alternatively, the data suggest that the increase in protein 
levels could result from removal of inhibition on translation of the wild-type transcript. 
Such inhibition could arise from competition for translation from the mutant transcript, a 
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concept that would be consistent with observations on translational competition in 
Drosophila (Gebauer et al., 1999) and is supported by our finding that knock-down of 
the mutant transcript best correlates with rescue of the calamity phenotype through 
restoration of protein levels (Fig. 4). Although this proposed mechanism for the increase 
in functional protein is not directly testable under these conditions, if plausible this 
significantly broadens the applicability of the morpholino approach because it 
demonstrates that loss of one particular mutant form may be sufficient to cause rescue of 
protein function and phenotype, with only minimal increases in the amount of wild-type 
mRNA.  
     Taken together, the data reported here have several implications of direct relevance to 
the development of effective therapeutics in Menkes disease. Experimental (Gansner et 
al., 2007a; Mendelsohn et al., 2006) and clinical observations in affected patients (Tang 
et al., 2006) reveal that maintenance of central nervous system function in this disease is 
prioritized under circumstances of limited copper availability or decreased ATP7A 
function. This hierarchy of copper delivery suggests  that prevention of the 
neurodegenerative features in Menkes disease may be possible with therapeutic 
interventions that result in a modest increase in ATP7A within a specific developmental 
window. The in vivo rescue observed in these studies directly supports these 
pathophysiologic concepts and raises the potential for in utero interventions in this 
disease. The data in this paper demonstrate the utility of zebrafish for rapid screens to 
identify specific antisense sequences effective in phenotypic rescue. While morpholino 
delivery remains problematic, given the robustness of the assay reported here and the 
increasing number of zebrafish models of human genetic disease (Ackermann and Paw, 
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2003) these findings support further study of this technology in the development of 
effective therapeutics for inherited metabolic disease.  
Methods 
Animal maintenance. Fish stock maintenance was performed according to institutionally 
approved procedures. Embryos for experiments were obtained through in vitro 
fertilization and incubated at 28.5C. Wild-type fish were AB strain. The mutant calamity 
has been described previously (Mendelsohn et al., 2006). Mutagenesis of wild-type fish 
was performed using the chemical mutagen ethyl nitrosourea (ENU). Mutants were 
screened for the calamity phenotype comprising lack of pigmentation and notochord 
defects. Putative mutants were crossed to calamity to verify allelism. These were then out 
crossed to AB fish and grown to adulthood. Regions of genomic DNA containing 
putative mutations were sequenced in both AB and WIK strains to rule out the possibility 
of strain-dependent polymorphisms. 
 
Morpholino Synthesis and Injection. Morpholinos were synthesized by GeneTools, 
LLC. Morpholinos were dissolved to 2mM in water and stored at -80C. Injection of 
morpholinos was performed on a microinjection apparatus (Harvard Instruments). A 
constant volume (1.44nL) of morpholinos was injected at different dilutions of the stock 
(1:2 to 1:10) to optimize the dose which gave the strongest phenotypic effect while 
minimizing off-target effects. 
Molecular cloning and PCR. Total RNA was extracted from embryos using the Trizol 
reagent (Invitrogen). Random hexamer primed cDNA was synthesized using 
SuperScriptIII according to manufacturer’s protocol (Invitrogen). PCR was performed 
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using Phusion DNA polymerase (Finnzymes). High-resolution separation of products was 
performed on 10% TBE-polyacrylamide gels. All sequences were verified by direct 
sequencing. The L1316R clone of zebrafish atp7a was generated from the wild-type 
sequence using the QuickChangeII site-directed mutagenesis kit (Stratagene). The altered 
clone was sequenced and other PCR errors excluded. 
 
qPCR. qRT-PCR was performed using primers specific to either the mutant or wild-type 
form of the Menkes transcript. This was accomplished by designing primers that were 
complementary to the exon-exon junction affected in the mutant (Sup. Fig. 3A). The 
following primer sequences were used: Common forward primer 
ATGATGAGCTCCGGACAGAC. calamity specific reverse 
GGAATGATCTTTTCCACCTGAG. Wild-type specific reverse 
GGAATGATCTTTTCCACTGTCG. Total atp7a primers 
TGGAGCTTGTGGTCAGAGG and AGGGCAACTGAAGCGTAGAG. Ornithine 
decarboxylase primers ATCTGGATCTCCGTTTTGCT and 
CCGTTTTACGCAGTGAAGTG. Primer efficiencies were calculated in triplicate for 
each primer set using either wild-type or mutant cDNA respectively. Random hexamer 
primed cDNA was synthesized using SuperScript III (Invitrogen) according to 
manufacturer's protocol. Quantitative PCR  was carried out on an iCycler (BioRad) with 
iQ Sybr Green SuperMix (BioRad). Calculations were performed using the Pfaffl method 
and each bar in the figures is the average of 3 to 5 individually prepared embryo RNA 
samples. Relative to wild-type, all cal embryos had a 50% decrease in total atp7a 
transcript (data not shown). 
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Immunoblots. Twenty to thirty 48hpf zebrafish embryos were gently homogenized in 
sucrose homogenization buffer (250mM sucrose, 5mM Tris pH 7.4) plus protease 
inhibitors (Roche) and then spun at 100,000rpm in a table-top Beckman ultracentrifuge 
for 30 min. The pellet was then resuspended in 50L RIPA buffer. Alternatively, 48hpf 
embryos were manually deyolked and homogenized directly in RIPA buffer. Equal 
amounts of protein were loaded on 6% polyacrylamide gels. After transfer to 
nitrocellulose, immunoblotting was performed using a rabbit polyclonal antibody raised 
to a C-terminal peptide of zebrafish Atp7a. Anti-rabbit secondary antibody and ECL 
reagents were purchased from Pierce and used according to manufacturer’s 
recommendations. 
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Abstract 
 
Nutrient availability is an important environmental variable during development that has 
significant effects on the metabolism, health, and viability of an organism. To understand 
these interactions for the nutrient copper we used a chemical genetic screen for zebrafish 
mutants sensitive to developmental copper deficiency. In this screen we isolated two 
mutants which define subtleties of copper metabolism. The first contains a viable 
hypomorphic allele of atp7a and results in a loss of pigmentation when exposed to mild 
nutritional copper deficiency. This mutant displays incompletely penetrant skeletal 
defects affected by developmental copper availability. The second carries an inactivating 
mutation in the vacuolar ATPase that causes punctate melanocytes and embryonic 
lethality. This mutant, catastrophe, is sensitive to copper deprivation revealing overlap 
between ion metabolic pathways. Together, the two mutants illustrate the utility of 
chemical genetic screens in zebrafish to elucidate the interaction of nutrient availability 
and genetic polymorphisms in cellular metabolism. 
Author Summary 
Copper is an essential nutrient required for multiple biologic functions. Proper uptake, 
transport, and excretion of copper are critical for use of this metal while reducing its 
inherent toxicity. While several key proteins involved in this process have been 
identified, there are still gaps in our understanding of copper metabolism – particularly 
during early development. We have used zebrafish, a genetically useful animal model 
system, to study genetic interactions with copper deficiency during development. We 
treated mutant embryonic zebrafish with a chelator which reduces the level of available 
copper and screened for mutants which displayed a copper deficient phenotype only in 
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the presence of the chelator. We identified and characterized two mutants which advance 
our understanding of copper metabolism during the early periods of development as well 
as show an interaction between copper metabolism and another fundamental pathway, 
that of proton transport. Our results expand our knowledge of copper metabolism and 
illustrate the power of this type of genetic screen in zebrafish to elucidate mechanisms of 
nutrient metabolism. 
Introduction 
 Proper maternal nutrition is critical for early embryonic development. The Dutch 
Famine Study examined the consequences of nutrient deprivation on developmental 
outcome during severe food shortages near the end of the Second World War and clearly 
demonstrated that inadequate nutrient availability during human gestation increases the 
likelihood of developmental anomalies (Susser et al., 1998). From these initial 
observations arose the well-recognized link between maternal folate supplementation and 
the suppression of neural tube defects (Czeizel and Dudas, 1992). Despite overwhelming 
epidemiologic data indicating the benefits of folate and other nutrient supplementation 
we do not fully understand the genetics of predisposition to these abnormal 
developmental phenotypes when faced with suboptimal nutrient levels. There are several 
large difficulties in the study of these processes in mammals that have prevented faster 
progress. The first is that the genetics of mammals has been cumbersome. The second, 
and more important, is that development of placental animals occurs in utero making 
rapid detection of developmental phenotypes difficult. Finally, controlling the level of 
nutrient available to the developing embryo cannot be done with precision as it depends 
both on the genetics of the mother and the embryo as well as maternal nutrition.  
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 Copper is an essential nutrient which when absent results in severe developmental 
abnormalities. This is most clearly illustrated by Menkes disease (OMIM #309400), a 
rare X-linked disorder of copper metabolism. Patients with Menkes disease have an array 
of symptoms including seizures, neurodegeneration, hypopigmentation, and lax skin 
which result from decreased copper incorporation into critical enzymes such as 
dopamine-β-hydroxylase and lysyl oxidase (Menkes, 1988; Menkes et al., 1962). This 
usually fatal disease is caused by mutations in a copper transporter, ATP7A 
(NM_000052), which resides in the secretory pathway and is responsible for transport of 
copper into this compartment. The Menkes gene product is also responsible for placental 
copper transport. While patients complete in utero development apparently normally, it is 
clear from biochemical studies at birth that there are significant defects that arise from 
gestational copper deficiency (Kaler et al., 2008).   
In order to study the effects of developmental copper deprivation our lab has 
previously created a zebrafish model of severe copper deficiency (Mendelsohn et al., 
2006). High doses of the cell permeable copper chelator neocuproine cause embryonic 
zebrafish to exhibit a Menkes-like phenotype with neurodegeneration, hypopigmentation, 
and connective tissue defects. Isolation and cloning of the mutant calamity, which shared 
these same characteristics, revealed a loss-of-function mutation in the zebrafish 
orthologue of ATP7A (NM_001042720). In this current study we expand this model to 
study the effects of induced genetic alterations on the developmental response to mild 
copper deprivation. We describe two mutants sensitive to nutritional copper deficiency 
that illustrate the potential power of this approach to overcome the limitations of studying 
gene-nutrient interactions in vertebrate organisms and that define combinations of loss-
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of-function mutations of known ion homeostatic pathways that result in aberrant 
development.  
 
Results 
Copper Deficiency Screen 
In order to elucidate the molecular genetics of copper metabolism we performed a 
forward genetic screen for zebrafish mutants with enhanced sensitivity to subthreshold 
copper deficiency. To control copper levels zebrafish embryos were treated with the cell 
permeable copper specific chelator neocuproine which has been previously shown to 
cause a copper-deficient phenotype including loss of pigmentation and notochord defects 
at a dose of 1 to 10 M due to loss of cuproenzyme activity (Mendelsohn et al., 2006; 
Smith and McCurdy, 1952). Prior to screening, a subthreshold dose of 100 nM 
neocuproine was determined to cause no alteration in pigmentation in wild-type, haploid 
embryos. We then used this concentration of neocuproine to screen clutches of haploid 
embryos derived from F1 carriers of ENU-induced mutations. One half of each clutch 
was placed in 100 nM neocuproine at 3 hours post fertilization (hpf) and allowed to 
develop until 48 hpf when clutches were screened for loss of melanin pigmentation in 
50% of the embryos (Figure 1A). Only those clutches which had loss of pigmentation at 
100nM neocuproine but contained at least some pigmentation when untreated were 
scored as mutant. In this pilot screen we examined 700 F1 females and found five 
potential mutants. Seven hundred mutagenized haploid genomes at an estimated single 
locus mutation rate of 1.1x10
-3
  represents approximately a 65-70% coverage of the 
genome (Solnica-Krezel et al., 1994). Of the five potential mutants, four were confirmed 
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as true mutants as defined by the transmission of the neocuproine sensitive phenotype to 
the offspring. One of these mutants fit the “ideal” criteria (no defect in vehicle and 
complete loss of pigment in 100nM neocuproine in 50% of the haploid clutch) as 
illustrated in Figure 1A and subsequent analysis revealed important insight into the 
intersection of genetics with sub-optimal copper nutrition in early development. A second 
mutant reveals a role for proton transport in copper metabolism. The final two mutants 
were similar in phenotype to the first but full analysis has not been completed. 
 The first mutant isolated from the screen displayed normal melanin pigmentation 
when untreated but completely lost all melanin upon treatment with 100 nM neocuproine 
(Figure 1 B, C). Crossing this mutant with calamity
vu69
 (cal) which bears an inactivating 
mutation in the copper transport protein atp7a resulted in partial non-complementation. 
The compound heterozygote had no melanin in the developing retinal pigment epithelium 
(RPE) and normally distributed mild hypopigmentation over the rest of the body (Figure 
1 D). Based on the partial non-complementation we tentatively assigned this mutant as an 
allele of calamity, designated gw71.  
 The second mutant has a phenotype that is independent of neocuproine. Named 
catastrophe, this mutant has normally distributed melanocytes that are small and punctate 
(Figure 1E). Catastrophe (cto) is homozygous lethal at about 3 days post fertilization (3 
dpf). The heterozygotes have no overt phenotype. In addition, cto homozygotes display 
sensitivity to copper deficiency by losing all melanin pigmentation in 100 nM 
neocuproine (Figure 1F). Crossing cto with cal
vu69
 results in complete complementation 
(Figure 1G) including the observation that the double heterozygote is not more sensitive 
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to neocuproine than cal
vu69 
heterozygotes (data not shown). Thus, we continued our 
analysis on the basis that cto identifies a new locus involved in copper metabolism. 
  
A hypomorphic allele of atp7a 
 Chromosomal localization using the early pressure parthenogenesis method 
(Johnson et al., 1995) placed the mutation in cal
gw71
 (referred to below as gw71) near the 
centromere of chromosome 14, the known location of atp7a. Combining this data with 
the partial non-complementation, we hypothesized that this mutant represented a 
hypomorphic allele of atp7a and confirmed this by direct sequencing of the mRNA. 
Mutant atp7a was cloned and displayed 100% identity with the published atp7a sequence 
(NM_001042720) with the exception of a single base change present in both mutant 
clones, T3182G, which results in a single, non-conservative amino acid substitution, 
I1061S (Figure S1A). This mutation is located in a region highly conserved in copper 
transporting ATPases and exchanges a hydrophobic amino acid for one that is polar and 
hydrophilic (Figure 2A). This single amino acid change results in significant depletion of 
the full-length protein in mutant embryos (Figure 2B). 
To verify that this was the causative mutation in gw71, we performed an in vitro 
activity assay for the protein using wild-type and mutant atp7a. Fibroblasts from patients 
with Menkes disease which lack functional ATP7A were transfected with tyrosinase in 
combination with either wild-type or mutant zebrafish atp7a created via site-directed 
mutagenesis of the wild-type cDNA. These fibroblasts were then treated with increasing 
doses of neocuproine, fixed, and stained for tyrosinase activity using L-DOPA. Activity 
is dependent on both atp7a and tyrosinase cDNAs (Figure S1B and S1C). In contrast to 
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zebrafish mutant embryos, equal amounts of wild-type and mutant Atp7a were obtained 
via transfection in these fibroblasts (Figure 2D). L-DOPA staining of cells expressing 
mutant cDNA was only mildly reduced when compared with wild-type (Figure 2D vs. E) 
indicating that the mutant retains some transport function. Overnight treatment with 25 
nM neocuproine resulted in complete loss of tyrosinase activity in fibroblasts transfected 
with mutant, but not wild-type, atp7a though a reduction in staining was observed with 
wild-type (Figure 2F, G). These data suggest that this single mutation in atp7a not only 
affects steady-state protein levels but is also capable of reducing the functional capacity 
of the protein, leading to sensitivity to copper deficiency. 
The I1061S mutation is located in the intracellular loop which comprises the 
ATPase domain of the transporter (Figure 2H). Dimitriev et. al. have previously 
performed NMR spectroscopy on the homologous domain of the Wilson disease copper 
transporter, ATP7B, in the presence and absence of bound ATP and have derived from 
the resulting chemical shift data the residues important for ATP binding and hydrolysis 
(Dmitriev et al., 2006). We mapped the same region of Atp7a onto their model by 
sequence alignment (64% consensus, 49% identical) to better understand the potential 
effect of this mutation on protein function. The mutation in cal
gw71
 lies five amino acids 
away from a critical ATP binding residue, E1064, which is highly conserved from yeast 
to humans (Figure 2A and Figure S1D). While a mutation of a critical residue would be 
expected to significantly alter ATP binding or hydrolysis, a non-conservative mutation in 
the region of a critical residue might be expected to only slightly alter ATP 
binding/hydrolysis through minor shifts in regional structure. 
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gw71 mutants display post-embryonic sensitivity phenotypes 
 Because the gw71 allele is homozygous viable, we were able to examine several 
post-embryonic roles for atp7a. Adult homozygous mutant zebrafish placed in varying 
doses of neocuproine did not display an overt sensitivity phenotype (data not shown). 
However, further study revealed a maternal effect of this mutation on embryonic copper 
metabolism. Homozygous mutant embryos derived from heterozygous females had a 
normal quantity and distribution of pigmentation that was partially sensitive to 100 nM 
neocuproine which abolished pigment in the retinal pigment epithelium (RPE) and 
reduced pigment over the body of the fish (Figure 3A, B). In contrast, homozygous 
mutant embryos derived from homozygous mutant females had no pigment in the RPE 
and reduced pigment over the body; treatment of these embryos with 100 nM 
neocuproine completely abolished pigmentation throughout the embryo (Figure 3 C, D). 
The effect of the mother’s genotype on the embryonic phenotype indicates that though 
not overt, the adult homozygous mutant does have defects in copper metabolism 
demonstrated by a nutrient-deficient state in the offspring. Thus the sensitivity of the 
embryo to neocuproine is due not only to aberrant embryonic copper metabolism, as the 
embryos from heterozygous mothers are sensitive to copper deficiency, but also to a 
deficient maternal loading of copper into the egg as the phenotype is exacerbated by 
maternal homozygosity. 
 The importance of optimal copper nutrition during development is further 
illustrated by the presence of vertebral skeletal defects in homozygous mutants. 
Homozygous mutant embryos were stained at 21 dpf with alcian blue/alizarin red to 
reveal bone and cartilage respectively. These were compared with wild-type syngeneic 
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age-matched controls raised in the same manner. The wild-type fish had straight vertebral 
columns along the entire length with long, straight bony processes extending from each 
vertebra (Figure 3E). In contrast, homozygous gw71 fish displayed variable vertebral 
defects, most often a significant warping of the bony structures in the caudal-most region 
of the column caused by irregular length of vertebrae and defects in the joint angles 
(Figure 3F). In addition the bony processes were also shortened and bent. Consistent with 
the observations in embryos that the mutation in gw71 brings the homozygous embryo 
close to, but not over, a threshold for copper deficiency, the persistent skeletal defects in 
the juvenile fish were not fully penetrant. Whereas wild-type fish had no vertebral defects 
(n=26), a significant number (38%, n=60) of the gw71 fish contained defects (Figure 3G). 
 Incomplete penetrance of the defect in the homozygous mutant fish could be 
attributed to either separate subtle genetic interactions or to variable nutrient availability. 
We hypothesized that if the penetrance of the defects were based on nutrient availability 
then reducing the nutrient levels would worsen the defects and increase the penetrance 
and vice versa. We thus took gw71 mutant embryos and placed them in either normal egg 
water or egg water supplemented with 100 nM neocuproine or 500 nM CuCl2 from 3 to 
51 hpf  (48 hour exposure). In addition, two separate groups of embryos were treated 
with neocuproine from 16 to 64 hpf and from 30 to 78 hpf to determine if there was a 
window of developmental time critical for the genesis of later defects. At 21 dpf the 
larvae were stained with alcian blue/alizarin red and scored for the presence or absence of 
vertebral defects (Figure 3G). Untreated wild-type embryos (not shown) or wild-type 
embryos treated with 100 nM neocuproine from 3-51 hpf had no perceptible skeletal 
defects. Thirty-eight percent of gw71 embryos had skeletal defects and this number was 
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not significantly affected by treatment with 100 nM neocuproine or 500 nM CuCl2 from 
3-51 hpf. However, there was a 50% increase in the number of skeletal defects in gw71 
embryos treated with 100 nM neocuproine from 16 to 64 hpf. The larvae treated with 100 
nM neocuproine from 30 to 78 hpf died approximately 8 dpf from an unidentified cause. 
These results indicate an increasing sensitivity to mild copper deprivation as the embryo 
develops in the first 16-72 hrs. Further experimentation with smaller, more discrete 
treatment times might allow the determination of any developmental window required for 
the effects of copper on vertebral axis formation. 
 In addition to the presence of vertebral skeletal defects in fully ossified skeletons, 
larvae at earlier stages of development displayed hyperossification of vertebrae adjacent 
to defects in the vertebral column (Figure 3 H, I). Normal zebrafish bone ossification 
begins rostrally and generally proceeds caudally with the exception of the caudal fin 
vertebrae (Du et al., 2001). In gw71 this pattern is maintained (arrowhead in Figure 3 H) 
except for areas containing defects (arrow in 3H). The defects affected the joints between 
vertebrae and had differing degrees of connective tissue bulges which partially stained 
with alcian blue indicating the presence of some cartilaginous tissue in these defects 
(Figure 3H arrowhead). 
 
catastrophe contains a defect in proton transport 
Before mapping the catastrophe mutant it was important to determine the extent 
of the defect in copper metabolism. The loss of pigmentation in the mutants could result 
from toxicity in a “two-hit” model whereby the mutation damages melanocytes and the 
drug acts to further affect these already sick cells. Therefore we examined the sensitivity 
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of the mutant to another copper-dependent process – notochord formation. Notochord 
formation requires the action of the cuproenzyme lysyl oxidase and its family members. 
Both reduction in lysyl oxidase levels and copper chelation result in wavy, distorted 
notochords (Gansner et al., 2007b). Placing cto mutants in 2 μM neocuproine at 3 hpf 
resulted in wavy notochords in the mutant embryos at 24 hpf while having no effect on 
heterozygous or wild-type embryos (Figure 4A, B). This experiment indicates that the 
mutation in cto causes a global defect in copper metabolism and is not limited to 
melanocytes. 
 The mutation in cto was localized to chromosome 7 and further mapping reduced 
the region of interest to an approximately 1 Mbp region between markers z21519 and 
z43308 (Figure 4C). It was possible to assemble a nearly complete BAC contig between 
these markers using database BAC sequences (www.sanger.ac.uk/Projects/D_rerio/). 
This contig was scanned for potential genes using the FGENESH program 
(www.softberry.com) and comparing to the Ensembl database (www.ensembl.org). A list 
of candidate genes was generated from this comparison. To further refine the list, a 
database of zebrafish insertional mutants was scanned for mutants displaying a similar 
melanocyte phenotype (Amsterdam et al., 2004). Approximately 6 mutants in this 
database had punctate melanocytes, 5 of which had insertions in genes encoding subunits 
of the vacuolar (H
+
) ATPase (Atp6) (NM_199620). As the critical region in cto contained 
the d subunit of the V0 complex of the vacuolar ATPase we cloned and sequenced this 
cDNA in the catastrophe mutants. A single base pair change C406T present in the mutant 
resulted in a premature stop codon, Q136X (Figure S2). Sequence alignment with the 
human sequences (NM_004691) revealed a highly conserved protein sequence (94% 
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identical) that most closely aligned with the d1 subunit (Figure 4D). Further database 
searches did not reveal a second d1 subunit in zebrafish. 
 The significant identity between the human and zebrafish protein sequences 
allowed us to use an antibody directed against human ATP6V0D1 to examine the steady 
state levels of protein. We hypothesized that the early stop codon would result in a 
significant decrease in protein levels. Indeed, in 48 hpf embryos there is a near total 
reduction in Atp6v0d1 protein as compared with wild-type embryos (Figure 4E). Total 
loss of this highly conserved and essential protein (see below) may be the cause of the 
catastrophe phenotype; however, there remains some possibility that another, tightly 
linked mutation may contribute to the observed phenotype.  Based on significant 
experimentation in yeast a proposed quaternary structure for the vacuolar ATPase 
complex has emerged (Figure 4F) (Kane, 1995; Kane et al., 1989; Smith et al., 2003; 
Tomashek et al., 1997; Xu et al., 1999). In this model, the two main subcomplexes, V0 
and V1 have complementary functions of proton translocation and ATP hydrolysis 
respectively. The complexes are connected through several stalk subunits, v1d, v0d, and 
v1f (not shown). Loss of these connecting subunits in yeast results in total loss of activity 
of the complex (Bauerle et al., 1993). Thus in catastrophe, the loss of the v0d subunit 
would be predicted to result in complete loss of proton translocation throughout the 
embryo. 
 
catastrophe is sensitive to pharmacologic inhibition of proton transport 
 If the defect in catastrophe is loss of Atp6 function the heterozygotes might be 
sensitive to pharmacologic inhibition of this transporter. Consistent with this, wild-type 
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embryos placed at 24 hpf  in 200 nM concanamycin A, a potent and specific inhibitor of 
Atp6 (Huss et al., 2002), showed no apparent phenotype at 48 hpf (Figure 5A). However, 
treatment of embryos heterozygous for cto resulted in punctate melanocytes and CNS 
degeneration, resembling the mutant (Figure 5B). The mutants themselves appeared 
qualitatively worse, with further reductions in melanocyte pigmentation and worsening of 
the degenerative appearance (Figure 5C). 
 
Secretory pathway copper transport is altered in catastrophe 
 While it is apparent that loss of Atp6 results in altered cuproenzyme activity for 
two enzymes in the secretory pathway, it is unclear which step of global copper transport 
is affected in cto embryos. To address this we performed transplant experiments to 
determine the cell autonomy of the defect. Wild-type cells from actin::GFP transgenic 
zebrafish were transplanted into cto embryos and examined at 48 hpf for pigmented cells 
and GFP expression. Transplantation resulted in a few well-pigmented and stellate 
melanocytes over the head and body as well as clusters of pigmented retinal epithelial 
cells (Figure 5D). These same embryos were mosaic for GFP expression (Figure 5E). In 
body melanocytes the melanin obscured GFP fluorescence (Figure 5E arrowhead). In 
contrast, the retinal pigment epithelial melanocytes display GFP fluorescence in the 
central area not covered by melanin (Figure 5E arrow). From this we make two 
observations: First, the melanized melanocytes are derived from wild-type donor cells, 
and secondly, that nearby wild-type epidermal cells are not required for normal melanin 
pigmentation nor stellate appearance (Figure 5E arrowhead). Thus copper metabolism 
must not be significantly disrupted on an organismal level, as these wild-type 
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melanocytes in a mutant host still receive adequate copper for normal pigmentation. Also, 
the stellate appearance indicates that the defect that causes punctate pigment cells in cto 
is also cell-autonomous. 
 The transplant experiment addresses delivery of copper to each cell, but the 
uptake or distribution of copper within the individual cell could also be affected in cto 
embryos. We hypothesized that disruption of the transporter responsible for secretory 
pathway acidification would result in defects in copper metabolism in this compartment. 
To test this we examined the sensitivity of cto embryos to partial loss of Atp7a through 
the use of a morpholino. Previous work from our laboratory has demonstrated that 
melanin synthesis following loss of Atp7a is also cell-autonomous in the melanocyte 
indicating that knock-down of Atp7a will allow interrogation of the pathway on a cellular 
rather than organismal level (Mendelsohn et al., 2006). Injection of a splice morpholino 
previously shown to result in a copper deficient phenotype at a dose that does not cause 
pigmentation defects in wild-type or heterozygous embryos (Figure 5F) causes total loss 
of melanin pigmentation in cto embryos (Figure 5G). Thus cto embryos are sensitive to 
loss of the secretory pathway copper transporter, Atp7a. Embryos heterozygous for the 
cto mutation did not show sensitivity to the Atp7a morpholino indicating that near 
complete loss of Atp6 activity is required to sensitize to alterations in copper metabolism. 
At the same time, the cytochrome oxidase activity of mitochondria derived from cto 
embryos is no different from wild-type indicating that copper delivery to mitochondria is 
normal and that the defect in copper metabolism in cto embryos is limited to the secretory 
compartment (Figure 5H).  
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Subcellular morphology and melanosome formation is altered in catastrophe 
 The vacuolar ATPase has been implicated in diverse trafficking events within the 
cell and inhibition of this protein results in altered ion homeostasis, disrupted membrane 
trafficking, defective acid secretion, deficient protein degradation, and loss of protein 
sorting, endosomal recycling, and vesicular secretion (Dettmer et al., 2006; Hurtado-
Lorenzo et al., 2006; Liegeois et al., 2007; Lin et al., 2006; Malikova et al., 2004; 
Taupenot et al., 2005; Tawfeek and Abou-Samra, 2004). To examine the effect of loss of 
this protein on cellular morphology, specifically melanocytes, we performed transmission 
electron microscopy focusing on the pigmented cells. Thin (500 nm) plastic sections of 
48 hpf embryos stained with toluidine blue did not demonstrate any further gross defects 
in organismal or cellular morphology beyond those observed in the pigmented cells both 
of the epidermis and the retinal pigment epithelium (data not shown). Upon examination 
by electron microscopy in wild-type embryos both epidermal pigment cells as well as 
retinal pigment epithelial cells at 48 hpf display dark, uniformly round or ellipsoid 
melanosomes distributed throughout flat melanocytes (Figure 6A-C). In contrast, the 
melanocytes of cto embryos are rounded and contain few fully melanized melanosomes, 
many large vacuolated structures and small vesicles surrounded by rings of melanin 
pigment (Figure 6D-F). These latter structures have been identified as multi-vesicular 
bodies, the accumulation of which is reminiscent of early blocks in melanosome 
maturation found in the cappuccino, pallid, ruby-eye 2, and reduced pigmentation mice 
which are all models of Hermansky-Pudlak syndrome and have specific early defects in 
melanosome biogenesis (Nguyen et al., 2002). Thus among other abnormalities loss of 
proton transport results in early blocks in melanosome maturation. It is interesting to note 
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that there remains active tyrosinase which produces some melanin in these aberrant 
structures despite the loss of the proton transporting ATPase (Figure 6F). 
 
Discussion 
Genetic screen for gene-nutrient interactions 
 In this work we have used the power of forward genetic screens combined with 
the ease of ex utero nutrient level manipulation accessible with the zebrafish to study the 
relationship between specific genetic alterations, the levels of the essential nutrient 
copper, and their combined effects on the developmental phenotype of the embryo. From 
these experiments we have derived a nutrient-sensitive allele of a known copper 
transporter that results in a juvenile skeletal phenotype. We have also implicated the 
vacuolar proton pump in vertebrate copper metabolism and interconnect two ion transport 
proteins whose individual effects on the other would not otherwise have been 
appreciated. 
 The ex utero development of zebrafish provides an opportunity for manipulating 
the developmental levels of nutrients. Much success has been achieved in yeast using 
large libraries of compounds coupled with known deletion mutants to define the roles of 
many of the yeast proteins in cellular biology and metabolism (Hillenmeyer et al., 2008; 
Parsons et al., 2004). One major advantage of yeast is the ability to absolutely control the 
levels of different nutrients and pharmacologic compounds and to screen large numbers 
at a time; however, yeast lack the complexity necessary to extend such findings to multi-
cellular organisms and ultimately to understand human biology for the treatment of 
disease. Our work shows that the zebrafish model system can fill the niche in extending 
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the principles of the chemical genetic screen to a vertebrate organism. Zebrafish retain 
the advantage of environmental exposure control while only slightly reducing the ability 
to screen large numbers. They also provide a system with more complex phenotypes to 
be examined which can then be brought back to the study of the underlying cell biology 
of a multi-cellular organism, particularly as the genome sequence and rapid mapping 
techniques improve. 
  
Nutrient-sensitive hypomorphic allele 
 The first mutant which was isolated from our screen was a hypomorphic allele of 
atp7a. Animals bearing this allele have a normal pigmentation and notochord phenotype 
at 48 hpf but are sensitive to mild copper deficiency thus indicating that transporter 
function was impaired. This mutation reduced the protein levels to below the detection 
limits of our immunoblot demonstrating that only a fraction of wild-type protein 
expression is necessary to maintain a near-normal phenotype. This is consistent with our 
previous observations where very minor changes in Atp7a protein levels resulted in 
significant rescue of the calamity phenotype (Madsen et al., 2008). Also, the increase in 
severity of the cal
vu69
 allele upon incubation with neocuproine demonstrates that even in 
this model of severe Menkes disease, there is still residual protein function without 
detectable expression (Madsen et al., 2008; Mendelsohn et al., 2006).  Interestingly, when 
the gw71 protein was overexpressed in cell culture fibroblasts it was fully capable of 
loading copper into the secretory pathway as evidenced by the robust tyrosinase activity; 
yet, at the same time there was a clear sensitivity of this mutant transporter to copper 
levels. 
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 This mutant allele is not the first hypomorphic allele of atp7a. A less severe form 
of Menkes disease, Occipital Horn Syndrome, is also caused by mutations in atp7a. 
Children with this disease have many clinical problems similar to Menkes disease; 
however, as this syndrome is not fatal in early life other abnormalities can be appreciated 
including skeletal defects such as deforming hyperostosis and kyphoscoliosis (Horn and 
Tumer, 2002). In this context the gw71 mutant provides several important advances. 
First, within the screen itself it provides proof-of-concept that the screen design will 
result in the identification of critical proteins involved in copper transport and 
metabolism. Second, the gw71 allele is both viable and fertile which itself provides 
distinct advantages. Third, this allele demonstrates that only a fraction of wild-type levels 
of Atp7a protein are required for near-normal pigmentation and notochord formation, a 
result suggested by previous experiments (Madsen et al., 2008). Fourth, this mutant 
expands the hierarchy of copper metabolism previously described (Mendelsohn et al., 
2006). The differential effect on retinal pigment epithelial melanin versus the body 
pigmentation seen under a variety of genetic and environmental manipulations (Compare 
Figures 1D, 3B, and 3D) demonstrates an increased sensitivity of the RPE to 
derangements of copper metabolism. Fifth, the gw71 mutant displays an incompletely 
penetrant developmental hyperostosis phenotype which is easily detected. The proximal 
etiology of these defects is unknown. It may be related to lysyl oxidase activity which is 
important for zebrafish notochord development and is sensitive to nutritional copper 
status (Gansner et al., 2007b). The increase in penetrance with copper chelation suggests 
that the variability may be due to nutritional differences. The lack of rescue observed 
with copper supplementation could be due to an inability of this ion to be translocated by 
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the mutant Atp7a protein to the proper compartment. Alternatively, lack of rescue with 
copper could point to residual genetic heterogeneity leading to phenotypic differences. 
Whichever is the case, this aspect of the mutant phenotype may provide a model to 
further our understanding of this poorly understood defect. The viability of this mutant 
would allow a modifier screen to find mutations responsible for different aspects of the 
copper deficient phenotype as well as to detect any genetic variability leading to the 
incomplete penetrance observed in the mutant. 
 
Intersection of two ion-transporting pathways 
 Our second mutant contains an inactivating mutation in the vacuolar (H
+
) ATPase 
subunit, Atp6v0d1. While abolition of this protein results in loss of proton transport into 
the secretory pathway, the embryo is capable of developing relatively normally to about 
48 hpf when defects become visibly apparent. This lag is most likely due to the 
persistence of maternal protein and mRNA. At this time point the changes in melanin 
pigmentation patterns signal the visible presence of defects in proton transport. Grossly 
the melanocytes become punctate which, upon ultrastructure analysis, is shown to be a 
loss of mature melanosomes and a rounding of the cell body with vacuolization. The 
observed relationship between lack of melanosome formation and cellular morphology is 
not understood but may suggest a toxic effect of inappropriate melanization in the multi-
vesicular bodies seen with electron microscopy or may be due to a particular sensitivity 
of melanocytes to loss of proton transport. As it has been shown that the vacuolar ATPase 
is important for vesicular trafficking and endocytosis (Dettmer et al., 2006; Hurtado-
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Lorenzo et al., 2006), the distinct disruption of planar morphology in cto melanocytes 
may also be due to defects in these processes. 
 The sensitivity to copper deficiency of the remaining melanin implicates proton 
transport in the homeostasis of copper metabolism. That the notochord is equally 
sensitive to reduced copper demonstrates that the defect is not limited to the melanocyte, 
but rather that there is a universal decrease in the ability of copper to adequately reach 
secretory cuproenzymes. Since the effect on copper metabolism in cto mutants is only 
revealed in the context of sub-threshold copper nutrition, without a screen of this nature, 
this inter-relationship of two ion transport pathways in the vertebrate organism would 
never have been appreciated.  
There are two models which could explain the defect in cuproenzyme function 
when proton transport is compromised. The first is that an acidic pH is important for 
copper incorporation into the nascent cuproproteins within the secretory pathway. The 
second model is that a proton gradient is required for copper transport, to balance the 
charge transfer across the vesicular membrane. These models are not mutually exclusive 
and a combination of the two could result in the final phenotype.  
The data presented in this paper demonstrate the power of the zebrafish model 
system to examine gene-nutrient interactions as well as to delineate basic cell biologic 
pathways. Continuing with this methodology will provide more insight into the biology 
of copper metabolism in a vertebrate organism. It is easy to see how screens in zebrafish 
similar to the one we describe have the potential to investigate the genetics of not only 
copper or folate metabolism, but also that this approach could be easily extended to an 
array of other nutrients.  
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Materials and Methods 
Zebrafish Maintenance: Zebrafish were maintained in the Washington University 
Department of Pediatrics zebrafish facility according to institutional guidelines 
supervised by the Division of Comparative Medicine. 
Mutagenesis, Screen and Mapping: The specific alterations of these well-characterized 
techniques are available in the supplemental Text S1. 
Immunoblot:  Mutant 48 hpf embryos were identified phenotypically. Twenty to thirty 
embryos were manually dechorionated and de-yolked, lysed in 75 μL RIPA buffer 
containing 10 μL/mL Protease Inhibitor Cocktail III (Calbiochem). Unlysed material was 
removed by centrifugation at 1000 x g for 5 minutes. For Atp7a, 50-100 μg of lysate in 
Laemmli buffer with 10% β-mercaptoethanol, heating for 5 min at 65oC (not fully 
reducing conditions) was loaded on a 6% SDS-polyacrylamide gel. The protein was 
transferred to nitrocellulose and blotted for Atp7a using a custom polyclonal antibody 
raised against a C-terminal peptide (Madsen et al., 2008). For Atp6v0d1, 30-40 μg lysate 
in Laemmli buffer with 10% β-ME heated to 70o C for 5 minutes was loaded on a 12% 
SDS-polyacrylamide gel. The transferred protein was blotted for Atp6v0d1 using a 
mouse polyclonal raised to human recombinant protein at 1:1000 dilution (Abnova Corp). 
Other antibodies: Actin (Sigma) 1:5000, β-catenin (BD Biosciences) 1:1000. 
Me344 Cell Culture: The Menkes patient fibroblast cell line Me344 (gift of Mick Petris) 
was maintained in 10% FBS/DMEM with Pen/Strep/Glut. Transfections were carried out 
on coverslips using Lipofectamine 2000 (Invitrogen) at a ratio of Lipo2k:DNA of 2.5 for 
3 hours in Optimem (Invitrogen). The media was then replaced with 1% 
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FBS/DMEM/PSG. Neocuproine was added in DMSO to the indicated concentration and 
the cells incubated overnight.  
L-DOPA Staining: Performed as previously described (Petris et al., 2000). 
Alcian Blue/Alizarin Red Stain: Twenty-one dpf juvenile zebrafish were fixed overnight 
in 4% PFA in PBS and stained as previously described (Javidan and Schilling, 2004). 
Transplantation: Approximately 50-100 cells were extracted from wild-type (AB) 
embryos at the 1000 cell stage and placed in mutant embryos of the same age using a 
micromanipulator syringe and glass needle as described previously (Westerfield, 2000). 
Morpholino Injection: The atp7a splice morpholino e7 
(TGACAACATTAACATTCATACCCTG) (Madsen et al., 2008) was injected at a dose 
of 965 pg/embryo at the 1 cell stage in 10% phenol red. At 48 hpf the injected embryos 
were scored for pigmentation and genotyped. 
Cytochrome c oxidase Activity Assay: A crude mitochondrial fraction was prepared from 
groups of 45 embryos at 52 hpf by homogenizing in 250 mM sucrose, 10mM Tris pH 7.4 
with a loose-fitting glass-glass tissue homogenizer. The homogenate was spun at 700 x g 
for 10 minutes. The supernatant from this spin was centrifuged at 23,000 x g for 20 min 
to form a pellet containing mitochondria and large vesicles. The pellet was resuspended 
in 150 μL of sucrose buffer with protease inhibitors and n-dodecyl-3-D-maltoside was 
added to 1 mM and incubated for 10 minutes at 25
o
 C. Cytochrome c oxidase activity was 
monitored by measuring the decrease in absorption of ferrocytochrome c at 550 nm using 
the protocol described for the Cytocox assay kit (Sigma, USA). 
Transmission Electron Microscopy: Performed as described previously (Gansner et al., 
2007b). 
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Supplemental Text 
Supplemental Methods: 
 
Mutagenesis: Male AB strain zebrafish at 12 weeks of age were placed in 3mM N-ethyl-
N-nitrosourea (ENU) for 1 hour in the dark and then washed several times and allowed to 
recover for one week. This was repeated for a total of 5 exposures. The mutagenesis rate 
was monitored by crossing to nacre and scoring for mutant progeny. A rate of 1 nacre in 
2000 embryos was obtained by this method. These mutagenized males were then crossed 
to AB females to generate the F1 generation carrying a random array of ENU induced 
mutations. 
Screen: Clutches of eggs from F1 females heterozygous for random mutations were 
obtained and fertilized with UV-inactivated sperm to create gynogenetic haploid 
offspring (Fig 1A). At 3 hours post fertilization (hpf) half of each clutch was placed in 
100nM neocuproine, a dose empirically determined to be a threshold dose for 
pigmentation defects in wild-type AB haploid embryos in our egg water (35mg/L Crystal 
Sea Marinemix, Marine Enterprises Int. Baltimore, MD with 18.3MΩ deionized water). 
At 48 hours post fertilization clutches treated with neocuproine were scored for loss of 
pigmentation. If the treated half of a clutch lacked pigment, the untreated half was 
examined. If this half also lacked pigment the mutant was discarded; if it contained any 
pigment at all, it was retained for characterization. F1 females from which mutant 
clutches were derived were out-crossed to AB for maintenance and crossed to WIK strain 
males for subsequent mapping. Mutants were confirmed by transmission of the 
phenotype to subsequent generations. 
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Early Pressure Parthenogenesis and chromosomal assignment: Gynogenetic diploid 
mapping has been previously described (Johnson et al., 1995). Briefly, clutches of eggs 
from heterozygous carriers were fertilized with UV-inactivated sperm and immediately 
placed in a french press. At 1’20” a pressure of 8000psi was applied to the eggs and held 
for 5 min. The embryos were then removed from the press and raised as normal larvae. 
Simple sequence length polymorphisms (SSLPs, http://zebrafish.mgh.harvard.edu/) near 
the centromere of each chromosome were used to assign the chromosome containing the 
mutation, as mutants will have no recombination between the mutation and the 
centromere. Also distance from the centromere is estimated based on the percentage 
mutants in clutches derived in this manner. 
Fine Mapping: Haploid embryos were obtained as above from heterozygous AB/WIK 
females. At 48 hours post fertilization the embryos were sorted according to phenotype, 
the DNA was extracted individually using proteinase K/phenol/chloroform and known 
SSLP’s (http://zebrafish.mgh.harvard.edu/) were examined for linkage to the phenotype. 
Cloning: Mutant atp7a was cloned and sequenced twice from a single cDNA preparation 
using atp7a specific primers. Wild-type and mutant atp6v0d1 was similarly cloned using 
the following primers based on the database sequence (NM_199620). 
 
Allele-specific PCR: Detection of the cto
gw325
 mutation was accomplished using allele-
specific PCR with the forward primer AAGCTTCCTGGCCAATGAAGC, the mutant 
specific reverse primer GATGTTAACAGCCTCCATCTA, and a positive control reverse 
primer CCAAATCCTGTTCAGAGATGC using a 62
o
 C annealing temperature with 
standard Taq polymerase (Promega). 
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Conclusion 
 The studies described in this thesis have sought to elucidate the role of the critical 
nutrient copper in the development of the vertebrate zebrafish embryo. Severe copper 
deprivation caused by either nutritional deficiency or genetic deficiency results in several 
developmental phenotypes that phenocopy the human gentic disease, Menkes disease. 
Loss of cuproenzyme activity in either high-dose neocuproine treated embryos or in the 
mutant calamity results in loss of pigmentation and notochord defects. These are 
analagous to the hypopigmentation and basemement membrane defects observed in 
Menkes disease. Using this robust model of developmental copper deficiency I have 
sought to investigate further the genetics and cell metabolism of copper homeostasis. 
 Chapter 3 describes experiments which probe the possibility of early treatment of 
Menkes disease through correction of splice defects in zebrafish embryos which carry an 
inactivating mutation in atp7a. In human infants with Menkes disease there are subtle 
defects even at birth (Kaler et al., 2008) and most die by age 3. This implicates the 
protein in critical developmental processes. Also, it is possible that only a small amount 
of protein product may be necessary for restoration of function as evidenced by the 
disease Occipital Horn Syndrome. This latter disease is also caused by mutations in 
ATP7A but is less severe than Menkes disease and patients often survive to adulthood. If 
functional protein could be restored during early developmental periods, or if small 
amounts of functional protein could be maintained, this could offer promising therapies 
for severe Menkes disease.  
Morpholino oligonucleotides alter splicing events via steric hindrance of the 
splicing machinery and have been used previously in cell culture models to restore 
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normal protein various diseases. This approach had not been demonstrated to rescue an in 
vivo disease phenotype. We took advantage of two splice mutations in alleles of the 
zebrafish mutant calamity (atp7a) to test the ability of morpholinos to functionally 
correct splice defects and lead to rescue of the mutant phenotype. Through the use of a 
series of morpholinos across an exon-intron boundary we investigated the effects of small 
changes in targeting sequence on the ability of the morpholino to alter splicing. The 
results demonstrated a set of principles of morpholino targeting to aid in the design of 
further molecules. The lack of functional rescue in these experiments demonstrated one 
of the limitations of the approach in that it is not capable of correcting point mutations 
which might remain in the final mRNA depending on the specific splice mutation. 
 The same approach for an intron-exon boundary resulted in a similar set of useful 
observations of targeting and the corresponding splicing effects. Three of the 
morpholinos used were able to rescue the phenotpe of the mutant. Complicating the 
analysis was the lack of observable change in the wild-type mRNA levels with 
morpholino injection. There were significant shifts in the splicing profile to a second 
upstream cryptic splice site which would also result in non-functional protein. The rescue 
coupled with the difficulties in identifying the mechanism could have several 
interpretations. The most probable, in my opinion, is that very little correct splicing is 
required to generate enough protein necessary for partial function. This interpretation, if 
correct, makes any therapy of this nature for this particular disease promising in that only 
a small effect must be produced to have significant phenotypic amelioration. These 
results also help explain the hypomorphic allele described above and discussed below. 
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Chapter 4 describes the central part of this thesis, a genetic investigation of novel 
mechanisms of copper homeostasis under conditions of limited availabilty. This screen 
for mutants sensitive to copper deficiency was designed to use the phenotype of loss of 
pigmentation to screen mutagenized zebrafish for proteins involved in copper 
homeostasis. The combination of subthreshold doses of the chelator neocuproine and 
genetic mutations increased the specificity of the screen for copper metabolic defects and 
removed several pigment-only mutants from the analysis (2-3 out of 700). As we 
expected we identified two types of mutants. The first was a hypomorphic allele of atp7a. 
This mutation demonstrated the ability of the screen to identify proteins critical for 
secretory-pathway copper homeostasis. If more mutants were screened we would expect 
to also find the zebrafish orthologue of atox1. This mutant also revealed a maternal effect 
of the mutation on embryonic pigmentation and expanded the hierarchy of copper 
metabolism. A developmental skeletal phenotype characterized by premature ossification 
of notochord defects in juvenile zebrafish mimics defects seen in both Menkes disease 
and Occipital Horn Syndrome and further investigation might shed light on the 
mechanisms of these skeletal deformities. 
The second was a loss-of-function mutation in a critical subunit of the vacuolar 
(H
+
) atpase (atp6v0d1). This mutant had its own distinct phenotype but was globally 
sensitive to copper deprivation implicating the proton gradient within the secretory 
compartment in the metabolism of copper. Genetic intersection with loss of atp7a 
recapitulated the neocuproine phenotype demonstrating the specificity for particular 
cellular compartments. Defects in intracellular morphology confirmed the role of this 
protein in vesicle trafficking.  
 107 
Future Directions 
These experiments have advanced our understanding of developmental copper 
metabolism and provide a foundation and tools for further investigation. There are 
several major ways in which this research could be expanded. 
First, this was a relatively small screen of only 700 genomes. Further screening 
would potentially result in the identification of more interesting mutants. The two 
identified in this thesis demonstrated the sound nature of the screen approach and all that 
remains is to continue. One would expect to find more interesting intersections of copper 
homeostasis with other ion homeostasis as well as vesicular trafficking defects. We  also 
expected, but have not yet found, mild mutations in tyrosinase which would affect the 
kinetics of copper loading into this enzyme. Such a mutant would expand our 
understanding of the compartments in which copper is actually transported and the 
mechanisms by which copper enters proteins once it is released into the secretory milieu.  
Second, the identified hypomorphic allele opens another avenue for a similar 
approach to the same question. A modifier screen in this genetic background would be 
expected to find similar results as the neocuproine but might have the advantage of being 
more specific. It is also possible that there are mechanisms that would be sensitive to loss 
of copper with neocuproine but not with the weak allele, and vice versa. Thus this would 
be a complementary approach to continuing the original screen. 
Third, the hypomorphic allele also displays prominent notochord and skeletal 
defects which give a model system to study the mechanisms of this process during 
development. Both Menkes patients and Occipital Horn Syndrome patients have skeletal 
deformities but it is unclear what the role of copper in these processes is. This allele 
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represents a tractable model for studying this process, particularly as it relates to the 
developing organism. 
Fourth, the vacuolar atpase mutant has not been probed in depth for its effect on 
other phenotypes. This protein has been implicated in many cellular processes and no 
known knock-out exists. The ex utero development of the zebrafish embryo allows 
visualization of complex processes and the relatively normal development to 48 hpf 
might provide a system for evaluating the morphologic consequences of this type of 
severe disruption of cellular homeostasis outside of copper metabolism.  
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